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Abstract
The distribution, pharmacology and function of the arginine vasopressin (Avp) 1b receptor subtype (Avpr1b) has provedmore
challenging to investigate compared to other members of the Avpr eceptor family.A vp is increasingly recognised as an
important modulator of the hypothalamic–pituitary–adrenal (HPA) axis, an action mediated by the Avpr1b present on
anterior pituitaryc orticotrophs. The Avpr1b is also expressed in some peripheral tissues including pancreas and adrenal, and
in the hippocampus (HIP), paraventricular nucleus and olfactoryb ulb of the rodent brain where its function is unknown.
The central distribution of Avpr1bs is farm ore restricted than that of the Avpr1a, the main Avpr eceptor subtype found in the
brain. Whether Avpr1b expression in rodent tissues is dependent on differences in the length of microsatellite dinucleotide
repeats present in the 5 0 promoter region of the Avpr1b gene remains to be determined. One difﬁculty of functional studies on
the Avpr1b, especially its involvement in the HPAa xis response to stress, which prompted the generation of Avpr1b knockout
(KO) mouse models, was the shortage of commercially available Avpr1b ligands, particularly antagonists.R esearch on mice
lacking functional Avpr1bs has highlighted behavioural deﬁcits in social memorya nd aggression. The Avpr1b KO also appears
to be an excellent model to study the contribution of the Avpr1b in the HPAa xis response to acute and perhaps some chronic
(repeated) stressorsw here corticotrophin-releasing hormone and other genes involved in the HPAa xis response to stress do
not appear to compensate for the loss of the Avpr1b.
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Introduction
Argininev asopressin (Avp)i sacyclicn onapeptide that
exerts diverseb iological effectst hrough an umbero f
receptors( R),t hree of whichh aveb eenc lonedt od ate
in mammals; thev asopressinA vpr1a, Avpr1b and
Avpr2—Avpa lsob inds to thes tructurallyr elated
oxytocin (Oxt)r eceptor( Oxtr)w ithh igha fﬁnity.E ach
member of theA vp receptor family hasadiscrete
peripherald istributiona nd function;h owever,d ataf or
thec entral distributiono ft heser eceptors ares till
incomplete.T he Avpr eceptorf amilya re Gp rotein-
coupledr eceptors:theA vpr1aa nd Avpr1b subtypes are
both coupledt oG q/11 ands ignalv ia phospholipaseC
(Jarde ta l. 1987;T hibonniere ta l. 2001). TheA vpr2
receptors ubtype is coupled to G s which, when
activated,e levatesc AMPl evelsb yr ecruiting
adenylate cyclase.I ts houldb en oted that many
Gp rotein-coupled receptors (GPCRs)c ouple
to multiple signal transduction pathways,i ncluding
theA vpr1b( Thibonnier et al.2 001)—thism ay be
relatedt ot he number of receptors ands ignal
transduction components expressedi nagiven cell.
TheO xtrp redominantly signalsv ia G q/11 buti sa
promiscuousr eceptori nt hati tm ay signal througha
varietyo fd ifferent a subunits (Reversie ta l. 2005;
Chinia nd Manning2 007).T he tissue distributiona nd
physiological function of each receptor demonstrates
Avp’sp rimary function in ﬂuid balancea nd homeosta-
sis. TheA vpr1ai sp redominantly foundi nv ascular
smooth muscle wherei ti si nvolvedi nm aintaining
bloodp ressurev ia itsc lassical pressora ction( Koshi-
mizu et al.2 006).T he renalA vpr2 is responsiblef or
waterr esorptioni nk idneyc ollectingd ucts by promot-
ingt he translocationo fa quaporin-2 channels to the
plasma membrane (Knepper 1997). The Avpr1b
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of thep ituitary gland( Jard et al.1 986; Lolait et al.
1995). Avpi nh ypophysial portal blood acts on
pituitary Avpr1bst or elease adrenocorticotrophic
hormone( ACTH)a sp arto ft he neuroendocrine
response to stress (Antoni1 993).T he contractiono f
uterine smooth muscle duringp arturitiona nd milk let
down duringl actation area ctions mediated by Oxta nd
theO xtr. Thed istributiona nd functiono f
Avpr eceptorsi sn ot limitedt ot hose sitesm entioned
abovea nd allr eceptors except theA vpr2 aree xpressed
in theb rain.T he centralr olee acho ft hese receptors
playsh as noty et been fullye lucidatedb ut theg rowing
amount of data from pharmacological andk nockout
(KO) studiess uggestss omef unctionalo verlap (e.g.i n
modulating some social behaviour).
The availability of several speciﬁc ligands for these
receptorsh as considerably aided in the characteris-
ation of the Avpr1a, Avpr2 and Oxtr but, until
recently,r esearch on the Avpr1b has been hampered
by al ack of Avpr1b-speciﬁc ligands. Avpr1br esearch
has focussed primarily on the detection of receptor
transcript levels (indirectly inferring receptor protein
levels), genetic KO studies ande xperiments with the
naturally Avp-deﬁcient Brattleboro (di/di)r ats. This
review details recent pharmacological and KO data on
ther oleo ft he Avpr1b in brain, pituitarya nd
peripheral tissues with particular emphasis on its
function in theh ypothalamic–pituitary–adrenal
(HPA) axisr esponse to stress.
V1B receptor distribution
The Avpr1a and the Oxtr have been well characterised
in the rodentb rain and are thought to be the likely
substrates for central actions of Avpa nd/or Oxt
(deWiedetal.1993;Burbachetal.1995;Barberisand
Tribollet 1996).M orer ecentd ataf rom KO animals
suggest speciﬁc behavioural deﬁcits in social memory
andaggressionaredirectlyduetotheabsenceofcentral
Avpr1bs(Wersingeretal.2002).Thesearchforcentral
Avpr1bs has proved more elusive than thato ft he
Avpr1as and Oxtrsa st he shortage of speciﬁc ligands
has prevented binding studies to visualise the Avpr1b
protein. Nevertheless, an umber of studies utilising
immunohistochemistry and in situ hybridisation
histochemistry( ISHH) haves hown that the Avpr1b
is expressed centrally,w hile reverse transcription-
polymerase chain reaction (RT-PCR) and functional
studies haved emonstrated Avpr1bs in an umber of
peripheral tissues (e.g. Lolait et al. 1995; Vaccarie ta l.
1998; Hernando et al. 2001; O’Carroll et al. 2008).
Although the highest concentration of Avpr1bs is
found within anterior pituitaryc orticotrophs (Jard
et al. 1986; Antoni 1993; Lolait et al. 1995), several
studies suggest aw ide central (Barberis andT ribollet
1996; Vaccarie ta l. 1998; Hernando et al. 2001) and
peripheral (Lolait et al. 1995; Saitoe ta l. 1995;
Ventura et al. 1999; Oshikawa et al. 2004) distribution
in rodents. Analysis of various brain regions and
peripheral tissues suggests that Avpr1bt ranscript
levels mayb et oo low to be reliably detected by
Northernb lot analysis and often depends on RT-PCR
to detect possible Avpr1b expression (Lolait et al.
1995).Arecent distribution study using ISHH with
probes directed to 5 0 or 3 0 untranslated regions of the
Avpr1bm RNA details am ore restricted patterno f
Avpr1bm RNAi nm ouse brain than previously
reported (Young et al. 2006). The riboprobesu sed
by Younga nd co-workersh ad low sequence identity to
otherA vp receptorst om inimisec ross-reactivity with
related mRNA sequences. This study shows Avpr1b
mRNAt ob em ost prominent in the CA2 pyramidal
neurons of the mouse and human HIP while receptor
transcripts are also found in thep araventricular
nucleus (PVN) and amygdala, albeit at al ower level.
All of these studies infer receptor expression by
determiningm RNAt ranscriptl evels rather than
receptor protein levels. However, in the absence of
speciﬁc radiolabelled ligands of high-speciﬁc activity
(whichm ay notp rovide detailed anatomical resol-
ution), mRNA expression coupled with immunohis-
tochemical techniques can accurately reﬂect receptor
protein distribution and quantity.
The peripheral distribution of the Avpr1b is much
more restricted than that of the Avpr1a, which is
ubiquitously expressed( Oshikawa et al.2 004;
Fujiwara et al. 2007a). Avpr1b mRNA has been
detectedbyRT-PCRintherodentpancreas(Saitoetal.
1995; Ventura et al. 1999; Oshikawa et al. 2004),
adrenal gland (Grazzini et al. 1996; Ventura et al.
1999; Oshikawa et al. 2004),s pleen( Lolait et al.
1995; Oshikawa et al. 2004),k idney (Lolait et al.
1995; Saitoe ta l. 1995),h eart( Lolait et al. 1995;
Saito et al. 1995),l iver (Saito et al. 1995) and lung
(Lolait et al. 1995; Saito et al. 1995).A dditionally,t he
thymus (Lolait et al. 1995),c olon (Ventura et al.
1999),s mall intestine, bladder (Saito et al. 1995),
breasta nd uterus (Lolait et al. 1995) andw hite
adipose tissue( Fujiwara et al. 2007a) reportedly
contain Avpr1bm RNA,h owever, these have not been
ratiﬁed by all studies (e.g. only one out of ﬁve studies
observeA vpr1b mRNA in rodent liver). In any event,
the functional signiﬁcance of varying amounts of low
levels of Avpr1b mRNA detected by RT-PCR in whole
braino rp eripheralt issue samples is unknown.
Disparities between laboratories may reﬂect meth-
odological (e.g. detection of ampliﬁed PCRp roducts)
and/ors traind ifferences.T he mRNA-expressing
tissues where there appearst ob es trong functional
correlations are the pancreas anda drenal gland.
In the pancreas, Avph as been shown to act on
Avpr1bs presenti ni slets to stimulate the secretion of
insulinf rom b cells where it may act synergistically
with corticotrophin-releasing hormone (Crh) (Oshi-
kawa et al. 2004; O’Carroll et al. 2008). While
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through insulin release, it can also act in opposition to
this by stimulating glucagonr elease (Yibchok-anun
and Hsu 1998) and promoting hepatic glycogenolysis
(Kirke ta l. 1979). Importantly,A vp-mediated
glycogenolysis acts viat he Avpr1a subtype present in
hepatic tissue (Morel et al. 1992) suggesting bifunc-
tional but oppositer oles of Avpi ng lucose homeostasis
by employing two different receptor subtypes. Exactly
whichr ole Avpp lays in regulating glucose balance at
the pancreatic level is dependent on the local glucose
concentrationp resenti nt his tissue (Abu-Basha et al.
2002).O ne study on ag lucagon-secreting hamster a -
pancreatic cell lines uggests thatA vp-induced gluca-
gon secretion is mediatedv ia the Avpr1b since the
Avpr1ba ntagonist SSR149415 potentlya ntagonises
Avp’se ffects in these cells (Folny et al. 2003).
The speciﬁcity of SSR149415 has, however, been
questioned with evidence of activity in Chinese
hamstero vary celll ines expressing recombinant
humanO xtrs( Griffante et al. 2005; Hodgson et al.
2007).T his may be an important consideration, as
Oxtrsi na ddition to Avpr1bs are apparently present in
pancreatic islets (Oshikawa et al. 2004) and haveb een
shown to causei nsulin/glucagon release (Jeng et al.
1996; Yibchok-anun et al. 1999).O ne laboratoryt hat
used agonists and antagonists to Avp/Oxt receptors
(but notably none selective for Avpr1bs) in a -cell lines
(Yibchok-anun and Hsu 1998) and perfused rat
pancreas (Yibchok-anun et al.1 999) produced
contrastingr esults, thel atters tudy suggesting
glucagon secretion in response to Avp, andO xt is
mediated through the activation of Avpr1bsa nd
Oxtrs, respectively,r athert han any activity of Avpo n
Oxtrs. On the otherh and, studies in Avpr1b KO mice
suggest both Avpa nd Oxt can stimulate glucagon
secretion through Oxtrs( Fujiwara et al. 2007b).
Avpm ay play ar ole in the hypersecretiono fg lucagon
from the pancreas of diabetics (Yibchok-anun et al.
2004),w hich is likelyt oi nvolve theA vpr1b.
Pancreatic b cells isolatedf romm icel acking
functional Avpr1bs unsurprisinglyd isplay ab lunted
insulins ecretion (Oshikawa et al. 2004),r einforcing
the role of Avpr1bs in this tissue. Interestingly, further
studies with this Avpr1b KO line show an increased
sensitivity of Avpr1b KO mice to the metabolic effects
of insulin( Fujiwara et al. 2007a). Together with the
discoveryo fA vpr1b mRNA by RT-PCR in white
adipose tissue, Fujiwara andc o-workerss uggest that
the disruptioni ni nsulin–adipocyte signalling may
lead to altered metabolism of glucose in Avpr1b KO
mice. Whether this is due to al ack of Avpr1b inﬂuence
in the pancreas, white adipose tissue, or both, is
unclear.
Grazzini and co-workersd emonstrated the presence
of Avpr1b mRNAb yR T-PCR in the medullab ut not
in the cortex of the rat adrenal gland. The cortex
expresses Avpr1at ranscripts primarily in the zona
glomerulosa (Guillon et al. 1995; Grazzini et al. 1996)
where this receptor regulates steroid secretion in vitro
(Grazzini et al. 1998).T hese studies also show that
Avpp recursor mRNA and Avpp eptidea re presenti n
the adrenal medullas uggesting Avpc an be released
withint he tissue, possibly acting in an autocrine/para-
crine mannert or egulate adrenal function. Stimu-
lation of the Avpr1b in the rat adrenal medulla causes
catecholamine secretion( Grazzini et al.1 998).
The presence of Avpr1as in the adrenal cortex and
Avpr1bs in thec hromafﬁn cellso ft he medulla
provides strong evidence of an independent modula-
toryr ole of each receptor in discrete regions of adrenal
tissue. The presence, however, of both Avpr1s in the
human( Grazzini et al.1 999) adrenalm edulla
indicates ap ossible co-expression of Avpr1r eceptors
in somes pecies. This suggests ap ossible overlap of
function distinct from the roles already noted and may
reﬂect the action of Avpo riginating from different
sources (e.g. pituitaryv s. local tissuer elease (Gallo-
Payeta nd Guillon 1998)), althought he medullaryc ell
type that expresses Avpr1as has yett ob ei dentiﬁed.
Notably, the plasma catecholamine response to forced
swimming and sociali solations tressi sa ttenuated in
Avpr1bK Om ice (Itoh et al. 2006).
The central, pituitarya nd peripherale xpression of
the Avpr1bg enem ay be inﬂuenced by activity of
elements in the upstream Avpr1bp romoter region.
Invitro studies usingcells transientlytransfected with a
rat Avpr1bg ene promoter sequence have identiﬁed
regulatoryG AGAr epeats that inﬂuence Avpr1b gene
transcription( Volpi et al. 2002). This provides a
possible mechanismo fp hysiological Avpr1b gene
regulation that may enable different levels of Avpr1b
expression in different tissues or species. When we
compared the 5 0 microsatellite region in the 5 0 Avpr1b
promoter sequenceo fd ifferent mouse strains, am ajor
size differencei nm icrosatellite length between the
C57BL6J/OlaHsds traina nd Balb/cOlaHsd and
129S2/SvHsd strains was observed( see, Figure 1A).
Further analysis of the sequence details differences in
thenumberofCTandCArepeatsbetweenstrains(see,
Figure 1B)t hat mayc onfer changes in promoter
activity.B asal promoter activityof aB alb/c 5 0 fragment
is threefold greater than that of the C57BL/6 strain
conﬁrming an increase in Avpr1b promoter activity
with the “long” formo fm icrosatellite (see, Figure 1B
and C), in ar eporter assay in COS-7c ells. The impact
of microsatellite DNA sequences on receptor
expression andb ehavioural phenotypesh as been
examinedinstudiesontheeffectsofAvpr1aexpression
onsocialbehaviourinvoles.Afﬁliativebehaviourssuch
as pair bonding haveb een attributed to changes in
Avpr1ae xpression patterns caused by microsatellite
length variations in the 5 0 Avpr1a regulatoryr egion
(Hammock andY oung 2002; Hammock and Young
2005).D ifferences in Avpr1b protein expression that
result from variancesi ng enep romotera ctivity
J. A. Roper et al. 100between mouse strains mayb eac ontributing factor to
varying susceptibilityt os tress. Several neurogenic,
psychogenic and systemic stressorsh aveb een tested in
different strains of micet or eveal as train-dependant
stressr esponse (Anisman et al. 2001). Interestingly,
C57BL/6ByJ miced isplay higher levels of plasma
CORTasw ella si ncreases in stress-related behaviours
comparedt ot he Balb/cByJs train, strengthening
supportf or Avpr1b’si nvolvement in mouse stress
susceptibility (Anisman et al. 2001).I ti si mportant to
note,h owever, that similar 5 0 microsatellite sequences
are not presenti nt he human Avpr1b gene.
Ther elativelyr ecente mergence of data from
genetic KO studies and the development of promising
pharmacological compounds haveg iven the task of
characterising the function of central andp eripheral
Avpr1br enewed vigour. Avpr1b KO micet ogether
with the long-standing subject of Avpr esearch, the
Brattleboro rat, serve as robust systems with whicht o
study the role of the Avpr1b and Avpi nt he HPAa xis
response to stress.
The HPAa xisa nd stress
The complex homeostatic controlt hat constantly acts
to resist challenges and ﬂuctuations in the internal
environment that may threaten the survival of an
organism is necessaryf or life. As ar esult of any
deviation in conditions, ah ost of physiological and
behavioural changes occur that allow an organism to
adaptt os uch challenges and restore the homeostatic
balance. One such neuroendocrine system that is
activated in stressful circumstances is the HPAa xis.
The end product of HPAa xis activation is an increase
in circulating glucocorticoids that, togetherw ith other
stressm ediators, act on target cells to enable the
organism to cope with the stress. Consequences of
elevated glucocorticoids are widespreada sc ytosolic
glucocorticoid receptorsa re present in most central
and peripheral tissues. The most profound effects of
elevated glucocorticoid levelsa re immunological and
metabolic changes. Glucocorticoids ecretion, in
concertw ith catecholamine release due to rapidly
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Figure 1. (A) PCR analysis of the microsatellite region in the 5 0
promoter of the mouse Avpr1b gene using genomic DNA from three
differentmousestrains(1,2,Balb/cOlaHsd;3,4,129S2/SvHsd;5,6,
C57BL/6JOlaHsd). The PCRproductswereg eneratedusing 100ng
genomicD NA,0 .5 units of AmpliTaq polymerase (Applied
Biosystems, Warrington, UK) and primers: upstream 5 0 GCGA GC
TCTTTCACACAT GCCTAGG3 0 incorporatingSacIrestriction
site (underlined); downstream 5 0 CAGG AT CCAC TG AGCA CC
AACT CAC3 0 incorporating aB amH1 restriction site (underlined)
with cycling conditions of 958 C1min followed by 40 cycles of 948 C
for 1min, 62.58 C1min, 728 C3 0sfollowed by aﬁ nal 728 Cs tep for
10min and a4 8 Cs oak. Gel electrophoresis (2% agarose) of a1 5-m l
sample from the 50-m lr eaction volume revealed a3 01bp product
(bp1755–2055) with Balb/cOlaHsd and 129S2/SvHsd DNA
templates and a , 186bp product with C57BL6J/OlaHsd strain
DNA template. The PCR products were subcloned into pGEM4Z
vector using Bam-H1 and Sac-1 restriction enzymes and sequenced.
(B) Alignment of 129SVand C57BL strain microsatellite sequences
between bases 1801 and 1988 of Genbank Acc#AF152533 (ending
824 bases upstreamo ft he initiating ATGc odon). Microsatellite CA
and CTrepeats are highlighted with dashes representing nucleotides
thatareabsentintheC57BLmouse5 0 promoterregionthatgivesrise
to the shorter sequence.T he longer formi sp resent in 129/Svj, J1,
SWR/J, AKR/J, FVBa nd CD1( USA) 129S2/SvHsd and
Balb/cOlaHsd( UK)s trains, whereast he shorter form is in
C57BL/6Ncr (USA),C 57BL/6JOlaHsd( UK)a nd C57BL/6J
(USA) strains.( C) Fragments of 5 0 Avpr1b gene promoter region
incorporatingthemicrosatelliterepeatsweregeneratedbyPCRusing
100ng genomic DNA, Herculase II Fusion DNA polymerase
(Stratagene (Agilent Technologies), Stockport,U K), and primers
corresponding to a , 1.1kb region of the mouse Avpr1b gene
(from bp1755–bp2823, Genbank accession number AF152533)
using genomic DNA extracted from the Balb/c, C57BL/6 and
129Sv mouse strains (Harlan, Bicester, UK). Ampliﬁed fragments
from each strain weret hen subcloned into ap GL3 basic dual-
luciferase reporter assays ystem (Promega, Southampton, UK) for
expressioninCOS-7cells.Values(mean ^ SEM)areexpressedasa
percentage of control pGL3 basic activity.T he promoter activity of
vectorsc ontainingB alb/c and 129Sv constructs is , 3 £ greater
than that of C57BL/6 ( *** ¼ P , 0.001).W hent he Balb/c
microsatellite region was replaced with the C57BL/6 microsatellite
sequenceintheBalb/creporterconstruct,activitydiminishedtothat
of the C57BL/6 strain.
R
Function of vasopressin Avpr1b 101activated sympatho-adrenomedullarys ystem, pre-
pares tissues for the physical “load” that may be
requiredb yt he body as parto facoordinatedr esponse
to manageo rt ackle the stress.
The HPAr esponse to stressr elies on several key
mediatorst hat ﬁne-tune glucocorticoid release, which
is dependent on an umbero ff actorss uch as the nature
of the stressor and the immunologicals tateo ft he
organism, tailoring the response to the speciﬁc stressor
concerned. Whens ubjected to as tressor, the
challenge is perceivedi nb rain regions appropriate to
the nature of the stressor. Interpretation of these
signals in relevant brain areas, such as various limbic
or hindbrain regions, leads to activation (or inhibition)
of the PVN (Hermane ta l. 2003).
The parvocellular subdivision of the PVN (pPVN)
is the most important site among several hypothalamic
nucleit hat regulate the HPAr esponse, as this is where
stress signals are integrated anda djusted before
peripheral signalling is initiated.O ncea ctivated,
pPVNp rojections that terminatei nt he external
zone of the median eminence release Avpa nd Crh into
the hypophysial portal blood (Antoni 1993). These
two ACTH secretagogues act on Avpr1bs and Crh
type 1r eceptors( Crhr1; coupled to G s anda denylate
cyclasea ctivation) present in pituitaryc orticotrophs
causing the release of ACTH into the peripheral blood
system. ACTH via melanocortin receptorsp resenti n
zona fasciculata cellso ft he adrenal cortex stimulates a
rapid secretion of glucocorticoids into the peripheral
blood supply.G lucocorticoids such as corticosterone
((CORT) in rodents) and cortisol (in humans)i nt urn
provide negative feedbackc ontrolo ft he HPAa xis via
pituitary, pPVN and higher brain centreg lucocorti-
coid receptors( e.g. HIP).
The dominance of Crh as the primary ACTH
secretagogue is still the prevailing view; however,
numerous direct andi ndirect neuronal inputs into
the pPVN, as well as humoral inﬂuences from blood
or cerebrospinal ﬂuid-bornes tress signals, dynami-
cally modulatet he contribution of Crh to the stress
response. The inﬂuence of Avp/Avpr1b mayb eo f
greater signiﬁcance than that of Crh/Crhr1 in some
stressc ircumstances, such as in response to some
chronic (repeated) stressors( Ma et al. 1999) or to
novel stressorss uperimposed on ar epeated stress
paradigm (Ma et al. 1997).E vidence of as witch
from Crh-ergic to vasopressinergic pPVN drive in
response to some chronic stressorsr einforces the
concept thate achr esponse is tailored to that speciﬁc
stressor andt hatA vp mayb ea ni ncreasingly
important mediator in these circumstances (Aguilera
1994;M ae ta l. 1999; Aguilerae ta l. 2008).
Moreover, studies of some speciﬁc acutes tressors
indicate that Avpm ay be preferentially released in
favour of Crh (e.g. insulin-induced hypoglycaemia
(IIH)i nr ats( Plotskye ta l. 1985), ketamine
anaesthesia and IIH in sheep (Engler et al. 1989)).
It is important to emphasiset hat in some species
(e.g. sheep andh orse) Avpr ather thanC rh appears
to be the main ACTH secretagogue (Engler et al.
1989; Alexander et al. 1997).
V1B receptor KO mice
Witht he generation of Avpr1bK Om iceb yu si n
2002, attention was initially directed towards the
deﬁcits observed in cognitive andb ehavioural tests
(Wersinger et al. 2002; Wersinger et al. 2004).I tw as
notedt hat mice lacking functionalA vpr1bs showed
impairments in social recognitiona nd reduced
responses in some aggression paradigms whereas
otherp hysiological and behavioural test responses
were normal (Wersinger et al. 2002, 2004, 2007a).
Findings from as econd Avpr1b KO line generated by
Tanouea nd co-workersi nitially focussed on the
disruptiono ft he HPAa xis (Tanoue et al. 2004),a nd
they reported that KO mice havel ower circulating
ACTH levels under basal and acutes tressc onditions.
This is in contrast to basal measurements of HPA
axis activity seen in our Avpr1b KO mouse colony,
whichm aintain normal restingA CTHl evels
(Lolait et al. 2007a). Notwithstanding basal HPA
axis differences, both Avpr1b KO lines have been
used to generate al arge amounto fc ompatible
evidence supportingt he involvement of the Avpr1b
in stress anda ggression, whichi sa lsol argely
consistent with in vivo Avpr1b antagonism with
SSR149415 (Griebel et al. 2002; Blanchard et al.
2005; Stemmeline ta l. 2005).
Reduced aggression in KO mice
Avph as been implicated as am oderator of several
central behaviourst hat were initially thought,b ased
on pharmacological proﬁles andd ue to its much
higherp revalence in the brain, to be mediatedb yt he
Avpr1a. Experiments in rodents, particularly ham-
sters, with Avpr1aantagonists haveconsistently shown
that Avpr1as facilitate somea ggressive behaviour
(Ferrise ta l. 1997, 2006; Caldwell and Albers2 004),
althought his is yet to be veriﬁed in Avpr1a KO
mutants(Wersinger et al. 2007b).It ispossible thatthe
neuralc ircuitryu nderlying aggression compensates
for the loss of the Avpr1a in the global Avpr1aK O. In
contrast, evidence of Avpr1b involvement in aggres-
sion comesf rom both pharmacological and KO data,
e.g.antagonism ofthe Avpr1bwith SSR149415 lowers
the frequency and duration of aggressive behaviour in
hamsters( Blanchard et al. 2005) while Avpr1b KO
miced isplay reduced attackn umber and longera ttack
latencyc omparedt ow ild types. This latter obser-
vation has been further categorised as ad eﬁcit in the
attackc omponent of aggression, as defensive aggres-
sion remains intact in mutant animals (Wersinger et al.
2002, 2007a). Furthermore, the reduced aggression
J. A. Roper et al. 102phenotype persists when Avpr1bK Om ice are crossed
with am ore aggressivew ild-derived mouse strain,
conﬁrming that the reduced aggression observedis not
simply ap eculiarity of laboratory mouses trains
(Caldwell and Young2 009).T he speciﬁc neural
substrate(s) vital for Avpr1b’sr ole in aggression is not
known, nori st he possible interaction between Avpr1a
and Avpr1b (or Oxt and the Oxtr for that matter—see,
Winslow et al. 2000) in vivo. It shouldb en oted that
the central distribution of Avpr1a- andO xtr-binding
sites and Avpr1b mRNA expression are clearly distinct
but may overlap in some brain regions (e.g. olfactory
system) (see, Table IIIi nB eery et al. 2008; Caldwell
et al. 2008a).
The changes in aggression,a sw ella sd ifferences in
socialm otivation (Wersinger et al. 2004) or social
memorye videnti nA vpr1b KO mice may be due to
deﬁcits in the processing of accessoryo lfactorys timuli
that are needed to evoke such behaviours( Caldwell
et al. 2008b). It is suggestedt hat the role of central
Avpr1bs may be to couple socially relevant cues
detected in the accessoryo lfactorys ystem to the
appropriate behavioural response (Caldwell et al.
2008b). Intriguingly,b oth Avpr1a andA vpr1b genes
aree xpressed in thef orebraino lfactory system
(Ostrowski et al. 1994; Hernando et al. 2001).
Evidence of pyramidal CA2 Avpr1bs (Hernando
et al. 2001; Younge ta l. 2006) also suggests a
relationship between the deﬁcits in social memorya nd
the uncoupling of socialc ues from the accessory
olfactorys ystem andt he formation or recall of
relevant memories (Caldwell et al. 2008b). Basedo n
studiesi nA vpr1b KO animals, the central Avpr1b
may also be involved in an umber of other behaviours
(summarised in Table I). Prepulse inhibition of the
startler eﬂex is attenuated in Avpr1b KO mice
(Egashira et al. 2005) suggestingt hat this mouse
may be as uitable model to investigate sensorimotor
gating. In contrast, no major changes in anxiety-like or
depression-like behavioursa re observed in Avpr1b
KO animals (Wersinger et al. 2002; Egashirae ta l.
2005; Caldwell et al. 2010).T hese results conspicu-
ously differf roms omeo ft hose obtainedi n
Brattleboro rats( Mlynarik et al.2 007) or with
Avpr1ba ntagonist administration, mainly in rats
(see below),a nd strongly suggest that the Avpr1bK O
Table I. Behavioural studies conducted in Avpr1b KO and wild-type mice that suggest central participation of the Avpr1b.
Behaviour/processB ehavioural paradigm/test Effect in Avpr1b KO Reference
Aggression Predatory( attack cricket) $ Wersinger et al. (2007a)
Maternal (pup defence) # Wersinger et al. (2007a)
Competitive (food deprivation/competition) # Wersinger et al. (2007a)
Defensive( attack avoidance) $ Wersinger et al. (2007a)
Defensive( retaliatorya ggression when attacked) # Wersinger et al. (2007a)
Offensive( resident intruder) # Wersinger et al. (2002)
Offensive( neutral arena) # Wersinger et al. (2002)
Memory/social memory&
recognition
Social memory( Bruce effect) # Wersinger et al. (2008)
Social recognition (familiar female recognition)
Morris water maze






Wersinger et al. (2002)
Wersinger et al. (2002)
DeVito et al. (2009)
DeVito et al. (2009)
Social motivation Bedding preference # Wersinger et al. (2004)
Sociability( familiar littermate interaction) # DeVito et al. (2009)
Sociability( investigation of novel animal vs.n ovel object) $ Yang et al. (2007)
Social dominance (mountingb ehaviour) " Caldwell et al. (2010)
Anxiety-related behaviour Ultrasonic vocalisation (nest separation/resident intruder) # Scattoni et al. (2008)
Anxiolytic effect of chronic SNRI treatment
(open armt est)
Open-ﬁeld,e levated plus maze




Ishizuka et al. (2010)
Wersinger et al. (2002)
Egashira et al. (2005)
Depression-like behaviour Forced swimming test $
$
Egashira et al. (2005)
Caldwell et al. (2010)
Inﬂuence of ethanol Voluntarye thanol consumption $ Caldwell et al. (2006)
Intoxicating effects of ethanol (e.g. motor co-ordination) $ Caldwell et al. (2006)
Prepulse inhibitionP repulse inhibitiono ft he acoustic startle reﬂex # Egashira et al. (2005)
Prepulse inhibitiono ft he acoustic startle reﬂex þ
atypical antipsychotic drug administration
$ Egashira et al. (2005)
Notes: Note that defensivea ggression behavioursa re less inﬂuenced by lack of Avpr1b than attacking behaviours. Furthermore, Avpr1b KO
mice not only show clear deﬁcits in social memory/recognition but also temporal order memory. Memoryd eﬁcits are not attributable to a
reduction in olfactoryp erformance that suggests the detection of olfactoryc ues remains unaffected but an altered processing of olfactoryc ues
results in the behaviour change.I nterestingly,d isruption in prepulseinhibitionto acousticstartle seen in Avpr1bKO miceparallels thatseen in
some human conditions such as schizophrenia and panic disorders. Injection of Avpr1b KO mice with atypical antipsychotics used to treat
schizophrenia appeared to reverse these deﬁcits.A rrowsi ndicate changes observedi nt he behavioural phenotypeo fA vpr1b KO mice
compared to wild-type animals.
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stress-induced anxiety or depression (e.g. see Kalueff
et al. 2007).
The stress response in KO mice
The impact of Avpi nA CTHr elease is often regarded
as ancillaryt oC rh as Avpa lone is aw eak ACTH
secretagogue but togetherw ith Crh it acts synergis-
ticallyt of acilitate ACTH secretion( Gilliese ta l.
1982; Rivier andV ale 1983; Antoni 1993). Not only
do thec orticotrophA vpr1b- andC rh-signalling
pathways converge to increaseA CTHr elease
(Abou-Samra et al. 1986),t he two receptors may
physically heterodimerise (Young et al.2 007). We,
and others,h aves ubjected adult Avpr1b KO animals
to an umber of acute andc hronic (repeated) stressors
of varying severity andn ature (Tanouee ta l. 2004;
Itoh et al. 2006; Lolait et al. 2007a,b; Stewart et al.
2008a,b). These studies clearly demonstrate that a
functional Avpr1b is essentialf or mounting an ormal
HPAr esponse, as manifested by increased plasma
ACTH levels, to most acute stressors( summarised in
Table II). The one exception is the response to
“severe” restraint where there is no difference in
either plasma ACTH level or CORTl evel between
Avpr1bK Oa nd wild-type mice (Lolait et al. 2007a).
Studiesi n“ severely”r estrainedB rattleboror ats
reveal as imilarp icture (Zelenae ta l. 2004).
It is likely that the restraintp roceduree mployed
was sufﬁciently stressful as to override any contri-
butionf romA vp (acting via the Avpr1b), e.g. ACTH
secretion may be entirely dependent on Crh acting
alone or in concert with other“ minor”A CTH
secretagoguess ucha sa ngiotensin II, vasoactive
intestinal peptideo rs erotonin (Carrasco and Van
de Kar 2003). Whenc omparing the reduced HPA
axis response to other acute stressorsi nA vpr1b KO
mice,w ec onsistently ﬁndadecreased ACTH
responseb ut nota lways ac orrespondingl ower
CORTl evel. The nature of stressorst ow hich both
ACTH and CORT, ACTH but not CORTa nd
neitherA CTH or CORTr esponses are reduced in
Avpr1bK Om ice does not fall into any existing
classiﬁcation of stress. This work is in agreement with
experiments in Brattleboro rats which suggest that
the magnitude of Avpc ontribution is dependento n
the context of the stressor (Zelenae ta l. 2009). As
shown in Table II,w eﬁ nd somea cute andc hronic
stressorsa re not inﬂuenced by the loss of the Avpr1b
(e.g. acute severe restraint), some have ar educed
ACTH response only (e.g. acutef orceds wimming
stress) and someh aveb oth ar educed ACTH and
CORTr esponse in Avpr1b KOsc ompared to wild
types (e.g. acute andr epeatedn ovel environment
stress). Thus, how Avpi nﬂuences the HPAa xis
response to stress could provide af urther basis of
stressor classiﬁcation.
Our studies in Avpr1bK Om ice (Lolait et al.
2007a,b;Stewarte ta l. 2008a,b) ands imilar studies on
Table II. As ummaryo fo ur recent studies with the Avpr1b KO colonyd emonstrating the effects of an umber of stressors on plasma ACTH
and CORTl evels in wild type vs.A vpr1b KO mice.
Avpr1b KO vs. wild-type mice Acute stress Repeated stress*





(Lolait et al. 2007a)
$ ( F ) $ ( F ) # ( F ) $ ( F )N o
Mild restraint
‡
(Stewarte ta l. 2008a)
# ( F ) $ ( F ) # ( F ) $ ( F )N o
Forced swimming
(Stewarte ta l. 2008a)
# ( F ) $ ( F ) # ( F ) $ ( F )N o
Novel environment
(Stewarte ta l. 2008a)
# ( F ) # ( F ) # ( F ) # ( F )N o
Shaker stress (see Figure 2) # ( F ) $ ( F ) $ ( F ) $ ( F )Y es (ACTH)
Lipopolysaccharide (LPS)
(Lolait et al. 2007b)
# 30min and 4h( C ) # 30min, $ 4h( C )
Ethanol (Lolait et al. 2007b) # ( F þ C ) # ( F þ C )
Insulin-induced hypoglycaemia
(Lolait et al. 2007a)
# ( F ) # ( F )
Antidepressants
(Stewarte ta l. 2008b)
# ( F þ C ) # ( F þ C )
Notes: This table highlights how the nature of the stressor can inﬂuence the effects of the Avpr1b on ACTH and CORTrelease. Stressors that
give rise to mismatches between ACTH and CORTd ata, and stressors that have showns ome level of adaptation after chronic administration
are shown. # ,H ormone values are reduced in KO mice compared to wild-type mice; $ ,h ormone values are unchangedi nK Om ice
compared to wild-type mice; * Plasma hormone levels measured following the ﬁnal acute stress in a1 0–14d aysd aily repeated acute stress
paradigm;
† “Severe” restraint, mice placed in a5 0mlf alcon tube with tissue paper packing inserted to restrict any movement of the animal;
‡ “Mild” restraint, mice placed in 50ml falcon tube.
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Zelena et al. 2009) both often note ad isparity between
stress-inducedA CTHv ersusC ORTr elease in
Avp/Avpr1b-deﬁcienta nimals.I ti si mportantt o
recognise that the CORTresponse to ACTH saturates
at low circulating ACTH levels( Dallmane ta l. 2002).
In addition, plasma hormones levels were only
measured at one time point in our studies so any
incremental changei nC ORTl evels mayh aveb een
missed. Furthermore,w eh avea ssumed that the
dynamics of stress-induced Avp, Crh and/or other
ACTHsecretagogueissimilarinAvpr1bandwild-type
mice. Where stress-induced ACTH release in Avpr1b
KO micei sn ot always followed by ap roportional
CORTa ttenuation, suggests that CORTm ay be
released independently of ACTH in some circum-
stances. Interestingly, this patterno fA CTH/CORT
proﬁlesi nr esponse to acutes tressa lso appearst ob e
presenti nn eonatal Brattleboro rats (Zelenae ta l.
2008).D iscrepancies between plasma stress hormone
levels appear stressor speciﬁcs uggestingt hata
particular stressor may possess speciﬁc characteristics
that coulda ctivate an umbero fp athwayst op romote
CORTr elease, e.g. viad irects planchnic or other
neurali nnervation of the adrenal cortex or medulla
(Ehrhart-Bornsteine ta l. 1998).A lternatively,a drenal
sensitivity to locally synthesised or humoral factors
may be altered permitting CORTr elease even when
low levelso fc irculating ACTH are present. Adrenal
hypersensitivitya nd ACTH-independent pathways of
CORTr elease would likelyb ypass the normal feed-
back controls that governA CTH release from the
pituitary( forr eview see Bornsteine ta l. 2008).
As mentioned above, chronic (repeated) stressh as
often been associated with an alteration in the control
of ACTH release from what is ap redominantly Crh-
mediated drive, seen in acutes tress, to an Avp-
mediated drive speculated to maintain ACTH levels
during adaptation to repeateds tress (Harbuz and
Lightman 1992; Aguilera 1994; Ma et al. 1997;
Aguilera andR abadan-Diehl 2000).A daptation to
repeated stress( i.e.l ower ACTH and/or CORT
following repeated stress compared to as ingle episode
of acute stress) is species ands tressors peciﬁc and is
nota lways observed (Marti andA rmario 1998;
Armario et al. 2004).T he apparent ﬂip in control
of ACTH release from Crh to Avpt hat is seen in some
repeated stressorsi nr ats (e.g. restraint) has made
Avpa nd the Avpr1b attractive targets for pharmaco-
logical intervention in conditionso fr epeatedo r
chronic stress, althoughi ts houldb en oted that
Avpd oes notp lay ar ole in HPAa xis responses to all
chronic stressors( e.g. chronic morphinei njection
(Domokose ta l. 2008)). The preferential expression
of Avpi nt he pPVN in adaptation to chronic stress
observed in rats is associated with an upregulation
of Avpr1bs (but not Crh receptors) in the anterior
pituitaryg land (Aguilera 1994).C hronic stressf rom
repeated (daily) exposure to an acute stressor leading
to ACTH hyperresponsiveness to as ingle, novel
stressor episode maya lso involvea ni ncrease in PVN
Avp( Ma et al.1 999) and pituitaryA vpr1b expression,
and pituitaryA CTHh yperresponsiveness (Aguilera
1994).H owever, Avp/Avpr1bd oes not appear to be
responsible for HPAa xish ypersensitivityt on ovel
stressors( Chen et al. 2008).T he mechanism(s) by
whichh ypothalamicA vp andp ituitary Avpr1b
responsiveness is maintained during stress adaptation
suggests the existence of numerous transcriptional and
translational regulatory components involved in PVN
and pituitaryp lasticity that dynamically alter Avpa nd
Avpr1bl evelsa ccording to demand( Volpi et al.
2004a,b). One view is that Avp/Avpr1bm ay alter
corticotroph proliferation and pituitaryr emodelling
during prolonged activationo ft he HPAa xis
(Subburaju and Aguilera 2007). However, studieso f
repeated stress in Avpr1b KO mice andB rattleboro
rats, suggest thatt he role of the Avpr1b and its cognate
ligandi nt he adaptation of ACTH/CORTl evelst o
chronic stressm ay not be as convincing as ﬁrst
thought.
Fort he chronic( repeated)s tressors tested in
Avpr1bK Om ice, there is ar eduction in the ACTH
response to aﬁ nal acutes tressf ollowing 10–14d ays of
stressr epeated once daily.T he responses of Avpr1b
KO animalsa nd wild-typea nimals exposedt o
repeated stressa re summarised in Table II. These
studiesh avean umber of salient features: ﬁrstly,a s
observed in male Brattleboror atss ubjected to
repeated restraint( Zelena et al. 2004),t he reduction
in the ACTH response following repeated stressi n
Avpr1bK Oa nimals is not often accompaniedb ya
similarr eductioni nC ORTr esponses—this mirrors
what we have observedi nt hese animals’r esponses to
acutes tress( see above). Secondly,w ith the exception
of the ACTH response to repeated, severe restraint,
the ACTH and CORTr esponsest oa cute or repeated
stressa re of equivalent magnitude. This suggests that
the Avpr1b participates in the fast ACTH secretion (as
seen in the response to acute stress) in repeatedly
stressed mice. Andﬁ nally,o fa ll the repeated stressors
studiedi nw ild-type mice from ourA pr1b KO colony,
adaptation in ACTH responses was only seen with
repeated exposure to shaker stress( SS) (Figure 2). No
adaptation in CORTr esponsesw as observed in
Avpr1bo rw ild-type mice following any repeated
stressp aradigm. There is ar obust plasma ACTH and
CORTi ncrease in response to as ingle, acuteS S
episode in wild-type mice; however, after 10 days of
repeated SS, the ACTH response is reduced in these
animals (see, Figure 2—graphA :p lasma ACTH
levels, wild-type acutes tress response vs. wild-type
chronic stress response). The acuteA CTH response
in Avpr1bK Om ice, while reduced from that seen
in wild-type animals,i st he same for repeated SS.
Furthermore, the ACTH response to repeated SS in
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wild-type mice. It is tempting to speculate that there is
al oss of adaptation to repeatedS Si nA vpr1b KOsb ut
such ac onclusion would be tenuous since ACTH
levels in acutely stressed Avpr1b KO mice are already
veryl ow.T he lack of functional Avpr1b in the KO
mice has such ap rofound effecto nt he ACTH
response to SS in these mice that any non-Avpr1b-
mediated adaptation to repeated SS is probably
negligible. The studies in Avpr1b KO mice and
Brattleboro ratsh ighlight the discrepancyb etween
Avp/Avpr1b-mediated ACTH and CORTs ecretion
during acute and repeated stress—this mayh ave
implications on the potential use of Avpr1b antagon-
ists to ameliorate symptoms of HPAa xish yperactivity
in stress-relatedd isorders.
Gene expression in Avpr1b KO mice
Whether the deﬁcits observedi nA vpr1b KO mice
outlineda bovea re ad irectr esult of disruptiono f
Avpr1bs ignalling pathways or the result of an altered
compensatorye xpression proﬁle is not known. As far
as HPAa xis function is concerned, clearly Crh
(or Oxt) does notc ompensate for the loss of the
Avpr1bi nA vpr1b KO mice. There are some direct
changes that occur in KO mice that give rise to
phenotypes such as altered glucose metabolisma nd
attenuated ACTH release;h owever, indirect changes
that affect behavioural systems that mayl eadt ot he
deﬁcits seen in Avpr1b KOsh avey et to be identiﬁed.
We have used ISHH to assess basal gene transcript
levels of an umbero fg enes that are closely linked with
HPAa xis function and ﬁnd no signiﬁcant differences
in gene expression between Avpr1bK Oa nd wild-type
mice( Figure 3). Comparisons of Oxtr mRNA levelsi n
Avpr1bK Oa nd wild-type mouse anterior pituitaries
appear to suggest an upregulation of Oxtrsi nA vpr1b
KO mice (Nakamurae ta l. 2008).A sO xt at high
concentrations can elicit ACTHr elease viat he
Avpr1b, and the Oxtr may be expressed in cortico-
trophs,i th as been suggested that increased expression
of Oxtrsm ay be ac ompensatorym echanism through
which Avpr1b KO mice and Brattleboro rats can, to
some degree, makeu pf or the lack of Avpr1b/Avp-
mediated ACTH release (Nakamura et al. 2008).
We cannott otally rule outt he possibilityt hat
mechanisms compensating for the loss of Avpr1b are
active in the Avpr1b KO.C hanges in neurochemical
networks active centrally (e.g. projections to the PVN
or signals within the PVN itself) or at the level of the
anterior pituitarya nd adrenal may have occurred. We
also cannot exclude ar ole of central Avpr1bs (or for
that matterA vpr1as) in directly or indirectly inﬂuen-
cing HPAa xis activity.N evertheless, stress-induced
ACTH levels in our Avpr1bK Os are consistently
lower (often to basal levels) than wild-type controls,
conﬁrming any compensation (e.g. from the action
of Crh) is not sufﬁcient to fully counteract the loss of
the Avpr1b (Lolait et al. 2007a,b; Stewarte ta l.
2008a,b). The role of potential Oxtr-mediated ACTH
release in Avpr1b KO mice and Brattleboro rats
remainst ob ec lariﬁed, however, as the Oxtr is
predominantly located in lactotrophs rathert han
corticotrophs in the anterior pituitary( Breton et al.
1995) it is likely that the Oxtr plays am inor role
Figure 2. Plasma hormone levelso fm ale wild type ( þ / þ )a nd KO ( 2 / 2 )m ice following acute and chronic (repeated) SS. Note that the
ACTH response to acute SS in wild type but not Avpr1b KO animals is signiﬁcantly reduced following repeated SS. Mice of appropriate
genotype generated from parental crosses heterozygous for the Avpr1b werer andomly assigned to an experimental group containing7 –8
mice. SS consisted of shaking mice in separate clean empty cages on as tandardb ench top orbital shaker (stroke: 38mm at 150rpm) for
10min. Mice were returned to their home cage for af urther 10min prior to sacriﬁce. Chronically shaken mice weres tressed once daily for
10 daysw hereas mice in acute groups wereh andled for 9d aysa nd stressed once on the 10th day.C ontrol mice were handled once daily and all
experiments were performed between 0900 and 1130hi na ccordancew ith UK Home Ofﬁce regulations (Animal Scientiﬁc Procedures Act
(1986)) and approvedb yt he University of Bristol Ethical Review Board. Plasma ACTH (graph A) and CORTl evels (graph B) were
determined by ELISA and EIA, respectively (IDS, Tyne and Wear, UK). Data are expressed as mean ^ SEM. Signiﬁcant differences are
denoted as ***: P , 0.001, NS: not signiﬁcant.
J. A. Roper et al. 106Figure 3. RepresentativeI SHH photomicrographs of gene expression in brain and pituitaryo fm ale Avpr1b KO and wild-type mice.
Riboprobesc orrespondingt ot he following sequencesw ereu sed: 5-HT1a receptor (Htr1a) (bp1230–1597 of Genbank Accession number
NM_008308),5 -HT2a receptor (Htr2a) (bp1884–2492 of Acc#NM_172812),5 -HT2cr eceptor( Htr2c) (bp1435–1965o f
Acc#NM_008312), brain-derivedn eurotrophic factor (Bdnf) (bp310–822 of Acc#AK017559), cannabinoid CB1R (Cnr1) (bp728–1040
ofAcc#Y18374),Crh(bp101–686ofAcc#205769),type1Crhreceptor(Crhr1)(bp160–528ofAcc#NM_007762),glucocorticoidreceptor
(Nr3c1) (bp439–958 of Acc#X04435), Oxt (bp1753–1865 of Acc# M88355), Avp( bp2966–3388 of Acc# M88354), intronic
Avp( bp1965–2406 of Acc#M88354) and pro-opiomelanocortin (Pomc) (bp145-620 of Acc#V01529). The intronic Avpp robe was targeted
towards intron 1o ft he Avp/neurophysin II gene to reﬂect heteronuclear RNA expression levels. These probes were obtained by PCR using
genomic DNA, or brain (Crhr1, Crh, Bdnf,A vp and Oxt) or pituitary( Pomc) cDNA from 129Sv mouse tissue as template. Restriction sites
wereincorporatedintothe5 0 endsofPCRprimerstofacilitatecloningofthePCRproductintovectorpGEM4Z.Theintegrityofallriboprobes
was veriﬁed by DNA sequencing. ISHH on 12m ms ections with
35S-labelledr iboprobes was performed as in ref.( Lolait et al. 2007a).
Function of vasopressin Avpr1b 107compared to the Avpr1b in wild-type animals.T he use
of conditional KOsa nd emerging pharmacological
developments will no doubt help clarify the contri-
butiono ft he pituitaryO xtr in acutea nd chronic
stress.
Emerging pharmacological data
An umber of agonists (suchas desmopressin,anA vpr2
agonist) and antagonists (such as relcovaptan, an
Avpr1aa ntagonist) are available and frequently used
to study the Avpr1a, Avpr2a nd Oxtr (forr eview see
Lemmens-Gruber and Kamyar 2006; Manning et al.
2008).S ome of these are in clinical trials or have been
approved for use as treatments in disorderss uch as
nocturnal enuresis andn eurogenic diabetes insipidus.
The search for Avpr1b pharmacological tools has
gained much impetusd ue to theirp otential as
treatments for conditions associated with chronic
stresss uch as anxiety andd epression (fors hortr eview
see Griebel et al. 2005; Arban 2007).T he most widely
used non-peptide Avpr1b antagonist, SSR149415,has
been used extensively in researchs ince its character-
isation in 2002 (Serradeil-Le Gal et al. 2002) (see,
Tables III andI V). SSR149415 is orally active and
inhibits some butn ot alla cute stressor-induced
ACTH release in rats( Serradeil-Le Gal et al. 2002;
Ramose ta l. 2006),a nd does nota ffect HPA
hypersensitivityt on ovel stressors( Chen et al. 2008).
The compound acts at the human Avpr1b and also has
some antagonist activity at the human Oxtr in vitro
(Griffante et al. 2005) but has high selectivitya nd
nanomolar afﬁnity for rodent forms of the Avpr1b
(Serradeil-LeG al et al.2 002). In micea nd rats,
SSR149415 has been tested in av ariety of classical
models of anxiety (e.g. elevated plus maze, light/dark
box test) and depression (e.g. forced swim test,
chronic mild stress) as well as otherm odels (e.g.
olfactoryb ulbectomy,F linder’ss ensitivel ine) that are
used to determine the efﬁcacyo fp otential anti-
depressant and anxiolytic drugs (Griebel et al. 2002;
Overstreet and Griebel 2005; Stemmelin et al. 2005;
Louis et al. 2006; Salome´ et al. 2006; Shimazakie ta l.
2006; Hodgson et al. 2007; Iijima and Chaki 2007).
Peripherala nd central pretreatmentw ith SSR149415
reduces anxiety andd epressive-related behaviour in
theset ests with high compatibility between the
ﬁndings of these studies. SSR149415 also reduces
aggressioni nh amsters( Blancharde ta l. 2005),
signiﬁcantly reversest he reduction in dentate gyrus
cell proliferation caused by chronic mild stressi nm ice
Table III. Summaryo fs tudies conducted with Avpr1b antagonists on HPAa ctivity in vivo.
Index of HPAa ctivity Effect of antagonist Compound/route/species Reference
Basal ACTH/CORT $ Org/iv/rat Spiga et al. (2009a)
Avp-inducedA CTH release # SSR* /ip &p o/rat Serradeil-Le Gal et al. (2002)
Avp-inducedA CTH release # SSR/iv/rat Chen et al. (2008)
Avp-inducedA CTH release # Org/iv/rat Spiga et al. (2009a)
Avp-inducedA CTH release # ABT-430 &A BT-558/po/mouse Behl et al. (2008)
Avp-potentiated Crh-induced ACTH release # SSR/po/rat Serradeil-Le Gal et al. (2002)
d[Cha
4 ]Avp
† /Crh-induced ACTH release # Org/po/rat Craighead et al. (2008)
dDAVP
‡ /Crh-induced ACTH release # Org/po/rat Craighead et al. (2008)
Acute restraint-induced ACTH release # SSR/ip/rat Serradeil-Le Gal et al. (2002)
Acute restraint-induced ACTH release # SSR/sc/rat Ramos et al. (2006)
Acute restraint-induced ACTH release # Org/iv/rat Spiga et al. (2009a)
Acute restraint-induced ACTH release # ABT-430 &A BT-558/po/mouse Behl et al. (2008)
Acute lipopolysaccharide (LPS)-
induced ACTH release
# Org/iv/rat Spiga et al. (2009a)
Acute ether-inducedA CTH release # SSR/ip/rat Ramos et al. (2006)
Acute footshock-induced ACTH release # SSR/ip/rat Zhou et al. (2008)
Acute noise-inducedA CTH release $ Org/iv/rat Spiga et al. (2009a)
Acute forced swimming-induced ACTH release $ SSR/sc/rat Ramos et al. (2006)
Chronic restraint-induced ACTH/
CORTadaptation
$ Org/sc/rat Spiga et al. (2009b)
Sensitisation ( " )A CTH response
to acute noise after acute or repeated restraint
# Org/sc/rat Spiga et al. (2009b)
Sensitisation ( " )A CTH response to acute
hypertonic saline after repeated restraint
$ SSR/po/rat Chen et al. (2008)
Notes: # ,H ormone values are reduced following Avpr1b antagonist administration; $ ,h ormone values are unchanged following Avrp1b
antagonist administration; * SSR ¼ SSR149415;
† d[Cha
4 ]Avp ¼ Avpr1b agonist;
‡ dDAVP ¼ Avpr2 agonist.
Sections were exposed to X-rayﬁ lm (HyperﬁlmMP,A mersham; GE Healthcare,L ittle Chalfont, UK) for hours (Pomc, Avp&Oxt) to weeks.
Sections hybridised with the corresponding sense probes gaven egligible, background staining (not shown). Brain regions showni nclude the
nucleusaccumbens(NA),PVN,supraopticnucleus(SON)andtheHIP.SectionsofbrainhybridisedwiththeNr3c1probewerecutatagreater
pitch around am ediolateral axisto obtain both HIPand PVN in one slice. Photomicrographswere takenat 6.3 £ magniﬁcation and resized for
publication( except Oxt, Avpa nd intronic Avpp robes which are magniﬁeda ppropriately to show the PVN or PVN/SON in greater detail).
R
J. A. Roper et al. 108(Alonsoe ta l. 2004) andb lockss tress-induced
hyperalgesia in rats (Bradesi et al. 2009).I th as also
been radiolabelled with tritium and used in receptor
autoradiography to reveal low-resolution binding in
the human and rat pituitary—no Avpr1b binding sites
were observedi ns ections of rat brain (Serradeil-Le
Gal et al. 2007).R ecently,S SR149415 has failed
phase II clinical trials (Kirchhoff et al. 2009). Overall,
the resultso fs tudies with SSR149415 evidence a
possible role for the Avpr1bi na ffective disordersa nd
point to animal model-validated targets with which to
treat them.









Aggression Offensive (resident-intruder) # SSR* /po/hamster Blanchard et al. (2005)
Anxiety-related behaviourF our-plate test # SSR/po/mouse Serradeil-Le Gal et al. (2002)
Punished drinking conﬂict test # SSR/ip/rat Griebel et al. (2002)
Punished drinking
conﬂict test
$ SSR/intraseptal/rat Stemmelin et al. (2005)
Elevated plus maze # SSR/po/rat Griebel et al. (2002)
Elevated plus maze $ SSR/intraseptal/rat Stemmelin et al. (2005)
Elevated plus maze # SSR/basolateral amygdala/rat Salome ´ et al. (2006)
Elevated plus maze # SSR/ip/rat Hodgson et al. (2007)
Elevated plus maze # SSR/dorsal( but not ventral)
HIP/rat
Engin and Treit (2008)
Light/dark test # SSR/ip/mouse Griebel et al. (2002)
Social defeat # SSR/po/mouse Griebel et al. (2002)
Defence test battery # SSR/po/mouse Griebel et al. (2002)
Social interaction test # SSR/ip/rat Overstreet and Griebel (2005)
Social interaction test # SSR/po/rat Shimazaki et al. (2006)
Separation-induced
pup vocalisations
# SSR/ip/rat Hodgson et al. (2007)
Conditioned lick suppression # SSR/ip/rat Hodgson et al. (2007)
Marble burying $ SSR/ip/mouse Hodgson et al. (2007)
Vogel conﬂict test $ SSR/ip/rat van Gaalen et al. (2008)
Vogel conﬂict test # ABT-436 &
ABT-558/ip/rat
van Gaalen et al. (2008)
Depression-like
behaviour
Forced swim test # SSR/po/rat Griebel et al. (2002)
Forced swim test # SSR/central nucleus
of amygdala/rat
Salome ´ et al. (2006)
Forced swim test # SSR/intraseptal/rat Stemmelin et al. (2005)
Forced swim test $ SSR/ip/mice &r at Hodgson et al. (2007)
Forced swim test # SSR/ip/rat van Gaalen et al. (2008)
Forced swim test # ABT-436 &
ABT-558/ip/rat
van Gaalen et al. (2008)
Forced swim test
(Flinder’ss ensitive line)
# SSR/ip/rat Overstreet and Griebel (2005)
Chronic mild stress # SSR/ip/mouse Griebel et al. (2002)
Chronic mild stress # SSR/ip/mouse Alonso et al. (2004)
Olfactoryb ulbectomy-
induced hyperactivity
# SSR/po/rat Iijima and Chaki (2007)
Olfactoryb ulbectomy-
induced hyperactivity
# SSR/ip/rat van Gaalen et al. (2008)
Olfactoryb ulbectomy-
induced hyperactivity
# ABT-436/ip/rat van Gaalen et al. (2008)
Tail suspension test $ SSR/ip/mouse Hodgson et al. (2007)
Differential reinforcement
of low-rate 72s( DRL-72s)
# SSR/ip/rat Louis et al. (2006)
Other FG 7142 (anxiogenic
benzodiazepine inverse
agonist)—induced central Ach
# (no effect of central
norepinephrine)
SSR/ip/rat Claustre et al. (2006)
Heroin seeking during tests
of reinstatement induced by
footshock or heroin primes
# SSR/ip/rat Zhou et al. (2008)
Stress-induced hypothermia $ SSR/ip/rat van Gaalen et al. (2008)
Stress-induced hypothermia # ABT-436 &A BT-558/ip/rat van Gaalen et al. (2008)
Stress-induced visceral hyperalgesia # SSR/ip/rat Bradesi et al. (2009)
Notes: # ,D ecreased behavioural phenotypei na nimals; $ ,n ob ehavioural change; * SSR ¼ SSR149415.
Function of vasopressin Avpr1b 109Around thes amet ime, SSR149415w as ﬁrst
reporteda sa nA vpr1b antagonist, the Avpp eptido
mimetic[ 1-deamino-4-cyclohexylalanine]a rginine
vasopressin (d[Cha
4 ]Avp) was described (Derick et al.
2002).T his agonist was the ﬁrst to show efﬁcacya t
nanomolar concentrations and stimulate the release of
ACTH/CORTw ithout exhibiting vascular or renal
activity (Derick et al. 2002). Other peptide agonists
selective for the rat Avpr1b haveb een generated by
modifying positions 4a nd 8o ft he Avpa nalogue
deamino-[Cys]arginine vasopressin (Penae ta l.
2007a).M any of thesem odiﬁed Avpa nalogues
display high selectivity for the Avpr1b andb ind with
sub-nanomolar afﬁnities (Pena et al. 2007a) and thus
could well be useful in the study of the Avpr eceptors
in rodents; however, they may be of limited use as
humant herapeutics due to their peptidergic nature.
The agonists created since d[Cha
4 ]Avp do, however,
havea ni ncreasingly reﬁned agonist proﬁle. One such
membero ft he recent modiﬁed range of Avpa nalogue
agonists, d[Leu
4 ,Lys
8 ]Avp, is noted to be af ull agonist
at human, rat and mouse Avpr1bs in vitro as well as
stimulates ACTH and insulin release at low doses
from mouse pituitarya nd perfused rat pancreas,
respectively( Pena et al.2 007b). Thise ffecto f
d[Leu
4 ,Lys
8 ]Avp on mouse and rat tissue is blocked
when co-administered with SSR149415 (Pena et al.
2007b).
Sincet he developmento fS SR149415,t here have
been some recent reportso fanon-peptidea ntagonist
(Org)t hati sh ighlys elective fort he humana nd
ratA vpr1b( Craigheade ta l. 2008).P retreatment
of rats with this compound causes as igniﬁcant
reductioni nA CTHr elease afterr estraint stress or
lipopolysaccharide(LPS) challenge(Spigaeta l.2009a)
andt oaheterotypics tressora fter repeated restraint
(Spiga et al.2 009b)( seeT able III).H owever, Orgd oes
nota ffectr epeatedr estraint stress-induced ACTH/-
CORTadaptation in rats (Spiga et al.2 009a). Another
seto fA vpr1ba ntagonists (ABT-436 andA BT-558)
have subnanomolar afﬁnityf or theh uman Avpr1b with
approximately3 0-fold lowera fﬁnity forr at andm ouse
Avpr1bs( Wernete ta l. 2008). Thesec ompounds
attenuatea cute restraints tress-inducedA CTHr elease
(Behle ta l. 2008) anda ppeart oh avei ncreased
anxiolytic-likea nd antidepressant-likep otency and
efﬁcacy compared to SSR149415( vanG aalene ta l.
2008). More recently,o ther non-peptidea ntagonists
have been described: “p”, at etrahydroquinoline
sulphonamide derivative, with high selectivity for
ther at andh uman Avpr1b (Kisa pproximately 21nM
and4 4nM, respectively)( Scotte ta l. 2009), and
compounds generatedf romaseries of pyrrole-
pyrazinone andp yrazole-pyrazinone derivatives which
also appear to show good selectivitya nd high potency
(e.g.,c ompound1 1p IC50 ¼ 8.4) for the human
Avpr1b expressedi nC hinese hamstero vary cells
(Arban et al.2 010)—too ur knowledget he effectso f
thesec ompounds on HPAa xisa ctivityo rb ehaviour
have notb eenr eportedt od ate.
In conclusion, thed istribution andf unctional
studieso ft he Avpr1b have established its major role
in the pituitaryw here it plays ap ivotal parti nt he
regulation of the HPAr esponse to stress, and in
particular to acutes tress. Additionally,w es ee several,
perhaps minor, metabolic ande ndocrine roles in the
periphery. Behavioural changes generated from exper-
iments in Avpr1bK Oa nimals,t ogether with recent
Avpr1ba ntagonist data, have highlighted am ore
elusive central role for this receptor. The behavioural
implications of Avp, acting viat he Avpr1b,i n
aggression and stress, andt he integral connection
between stress, anxiety and depression make the
Avpr1ba na ttractivet argetf or pharmacological
intervention. Increased Avps ecretion and enhanced
pituitaryr esponsiveness to Avph aveb een reportedi n
some subtypeso fd epression (e.g.m elancholic
depression)(see, Dinan andS cott 2005 for ar eview).
Furthermore, polymorphisms inthe Avpr1bg enehave
beenassociatedwithdepression(vanWestetal.2004),
childhood-onsetmooddisorder(Dempsteretal.2007)
and attention-deﬁcit hyperactivity disorder( van West
et al.2 009).T he progressm adei ng enerating
compoundss electivef or this receptorm ay have
considerable implications for potential treatments for
anumberofdiseasestates aswellas forAvpresearch in
general. The development of new compounds that can
be radiolabelled to high speciﬁc activity is ac ritical
step in Avpr1b research as determination of its central
distribution may well provide an anatomical template
to assign how changes in behaviourso rd iseases tates
are inﬂuenced. Further developments in molecular
(e.g. conditional Avpr1b KOs; the use of Avpr1b-
speciﬁc small-interfering RNAst os electively silence
Avpr1bg ene expression in speciﬁc brain regions) and
pharmacological tools for use in rodents and primates
(e.g. positron emissiont opography (PET) ligands, see
Schonberger et al. 2010) will help elucidate the full
function of the Avpr1b andt hus the therapeutic value
researchi nto this receptor may hold.
Acknowledgements
J.A.R received funding from the Neuroendocrinology
CharitableT rust (UK)a nd the Schering-Plough
Corporation; A.M.O’C received funding from the
Wellcome Trust andB BSRC. This researchw as
supported by theN IMHI ntramural Research
Program( Z01-MH-002498-21).S .J.L received
funding from the Wellcome Trust.
Declaration of interest:J .A.R and S.J.L have used
the Avpr1b antagonist Org (supplied by the Schering-
PloughC orporation) in unpublisheds tudies in mice.
The authorsa lone are responsible for the content and
writing of the paper.
J. A. Roper et al. 110Noticeo fc orrection
Please note that the following amendments have been
made to this paper, ﬁrst published Online Early 9
September 2010: the removal of ad uplication of text
within Table Ic aptiono np age 6; in Table IVon page
12, the heading ‘Anxiety related behaviour’ has been
moved up to the 2nd line in columno ne from its
previous position at line 12; and as pelling error,
incorrect year of publication and incorrect volume
details have been amended in the Zhou et al. 2008
reference list and citationsi nT ables III and IV.
References
Abou-SamraA B, Catt KJ, Aguilera G. 1986. Involvement of protein
kinase Ci nt he regulation of adrenocorticotropin releasefromrat
anterior pituitaryc ells. Endocrinology 118:212–217.
Abu-BashaE A, Yibchok-anun S, HsuW H. 2002. Glucose
dependency of arginine vasopressin-induced insulina nd
glucagon release from the perfused rat pancreas.M etab Clin
Exp 51:1184–1190.
Aguilera G. 1994. Regulation of pituitaryA CTH secretion during
chronic stress.F ront Neuroendocrinol 15:321–350.
Aguilera G, Rabadan-Diehl C. 2000. Vasopressinergicr egulation of
the hypothalamic–pituitary–adrenal axis: Implicationsf or stress
adaptation. Regul Pept 96:23–29.
Aguilera G, Subburaju S, Young S, Chen J. 2008. The parvocellular
vasopressinergic system and responsiveness of the hypothalamic
pituitarya drenal axis during chronic stress.P rog Brain Res 170:
29–39.
Alexander SL, Roud HK, Irvine CH. 1997. Effect of insulin-
induced hypoglycaemia on secretion patterns andr ates
of corticotrophin-releasing hormone, arginine vasopressin
and adrenocorticotrophini nh orses. JE ndocrinol1 53:
401–409.
Alonso R, Griebel G, Pavone G, Stemmelin J, Le Fur G, Soubrie P.
2004. Blockade of CRF1 or V1b receptors reverses stress-
induced suppression of neurogenesis in am ouse model of
depression. Mol Psychiatry9 :278–286.
Armario A, Valle ` sA ,D al-Zotto S, Ma ` rquez C, Belda X. 2004.
As inglee xposuret os everes tressors causesl ong-term
desensitisation of the physiological responses to the homotypic
stressor.S tress 7:157–172.
Anisman H, Hayley S, Kelly O, Borowski T, Merali Z. 2001.
Psychogenic,n eurogenic, andsystemicstressor effectson plasma
corticosteroneandbehavior: Mouse strain-dependentoutcomes.
Behav Neurosci 115:443–454.
Antoni FA.1 993. Vasopressinergicc ontrol of pituitarya dreno-
corticotropinsecretion comesof age. FrontNeuroendocrinol 14:
76–122.
ArbanR .2 007. V1br eceptors:N ew probes for therapy.
Endocrinology 148:4133–4135.
Arban R, Bianchi F, Buson A, Cremonesi S, Di Fabio R, Gentile
G, Micheli F, Pasquarello A, Pozzan A, TarsiL ,T erreni S,
Tonelli F. 2010. Pyrrolo[1,2- a ]pyrazine and pyrazolo[1,5-
a ]pyrazine: Novel, potent, and selectives eries of vasopres-
sin1b receptor antagonists.B ioorg Med Chem Lett 20:
5044–5049.
Barberis C, Tribollet E. 1996. Vasopressin and oxytocin receptors
in the central nervous system. Crit RevN eurobiol 10:
119–154.
BeeryA K, Lacey EA, Francis DD.2 008. Oxytocin and vasopressin
receptor distributions in as olitarya nd as ocial species of tuco-
tuco (Ctenomys haigia nd Ctenomys sociabilis). JC omp Neurol
507:1847–1859.
Behl B, Dreschner KU,v an Gaalen MM, Gross G, Netz A, Oost T,
SchoemakerH ,S ullivan JP,W ernet W. 2008. Inhibition of HPA
axis activation by the V1b receptor antagonists ABT-436 and
ABT-558. In:P roceedingso fS ociety forN euroscience,
Washington DC, USA. Abstract#560.17/FF5.
Blanchard RJ, Griebel G, Farrokhi C, Markham C, Yang M,
Blanchard DC. 2005. AVPV 1b selectivea ntagonist SSR149415
blocks aggressiveb ehaviors in hamsters. Pharmacol Biochem
Behav 80:189–194.
Bornstein SR, Engeland WC, Ehrhart-Bornstein M, Herman JP.
2008. Dissociation of ACTH and glucocorticoids. Trends
Endocrinol Metab 19:175–180.
Bradesi S, Martinez V, Lao L, Larsson H, Mayer EA. 2009.
Involvement of vasopressin 3r eceptors in chronic psychological
sress-induced visceralh yperalgesiai nr ats. Am JP hysiol
Gastrointest LiverP hysiol 296:G302–G309.
Breton C, Pechoux C, Morel G, Zingg HH. 1995. Oxytocin
receptor messengerr ibonucleic acid: Characterization, regu-
lation, and cellular localization in the rat pituitaryg land.
Endocrinology 136:2928–2936.
Burbach PJ, Adan RA, Lolait SJ, vanL eeuwen FW,M ezey E,
Palkovits M, Barberis C. 1995. Molecularn eurobiology and
pharmacology of the vasopressin/oxytocin receptor family.C ell
Mol Neurobiol 15:573–595.
Caldwell HK,A lbersH E. 2004.E ffect of photoperiod on
vasopressin-induceda ggressioni nS yrianh amsters. Horm
Behav 46:444–449.
Caldwell HK, Young WS. 2009. Persistence of reduced aggression
in vasopressin 1b receptor knockout mice on am ore “wild”
background. Physiol Behav 97:131–134.
Caldwell HK, StewartJ ,W iedholz LM, Millstein RA, Iacangelo A,
Holmes A, YoungW S, WersingerS R. 2006.T he acute
intoxicating effectso fe thanol are notd ependento nt he
vasopressin 1a or 1b receptors. Neuropeptides4 0:325–337.
Caldwell HK, LeeH -J,M acbeth AH,Y oung WS.2 008a.
Vasopressin: Behavioral roles of an “original” neuropeptide.
Prog Neurobiol 84:1–24.
Caldwell HK, Wersinger SR, Young WS. 2008b.T he role of the
vasopressin1 br eceptori na ggressiona nd others ocial
behaviours. Prog Brain Res 170:65–72.
Caldwell HK, Dike OE, Stevenson EL, Storck K, Young WS. 2010.
Social dominence in male vasopressin 1b receptor knockout
mice. HormB ehav5 8:257–263.
Carrasco GA, Vand eK ar LD.2 003. Neuroendocrinep harma-
cology of stress.E ur JP harmacol 463:235–272.
Chen J, Young S, Subburaju S, Sheppard J, Kiss A, Atkinson HC,
Wood S, Lightman S, Serradeil-Le Gal C, Aguilera G. 2008.
Vasopressin does not mediate hypersensitivity of the hypothala-
mic pituitarya drenal axis during chronic stress.A nn NYAcad
Sci 1148:349–359.
Chini B, Manning M. 2007. Agonist selectivity in the oxytocin/
vasopressinr eceptor family:N ew insights and challenges.
Biochem Soc Trans 35:737–741.
Claustre Y, RouquierL ,D esvignesC ,L eonetti M, MontegutJ ,
Aubin N, Allouard N, Bougault L, Oury-Donat F, Steinberg R.
2006. Effects of the vasopressin (V1B) areceptor antagonist,
SSR149415, and the corticotropin-releasing factor 1r eceptor
antagonist, SSR125543,o nF G7 142-induced increase in
acetylcholine and norepinephrine release in the rat. Neuro-
science 141:1481–1488.
Craighead M, Milne R, Campbell-Wan L, Watson L, Presland J,
Thomson FJ, Marston HM, Macsweeney CP.2 008. Character-
ization of an ovel and selectiveV 1B receptor antagonist. Prog
Brain Res 170:527–535.
Dallman MF,V iau VG,B hatnagar S, Gomez F, Laugero K,
Bell ME. 2002. Corticotrophin-releasing factor, corticosteroids,
stress, and sugar: Energy balance, the brain, and behaviour.I n:
Pfaff DW,A rnold AP,E tgen AM, Fahrbach SE, Rubin RT,
Function of vasopressin Avpr1b 111editors. Hormones, brain and behaviour. New York: Academic
Press.p5 71–631.
DeVito LM, Konigsberg R, Lykken C, Sauvage M, Young WS,
Eichenbaum H. 2009. Vasopressin 1b receptor knock-out
impairsm emoryf or temporal order. JN eurosci2 9:
2676–2683.
Dempster EL, Burcescu I, Wigg K, Kiss E, Baji I, GadorosJ ,
Tamas Z, KennedyJ L, Vetro A, Kovacs M, BarrC L. 2007.
Evidence for an association between the vasopressin V1b
receptor gene (Avpr1b) and childhood-onset mood disorders.
Arch Gen 64:1189–1195.
Derick S, Cheng LL, Voirol MJ, Stoev S, Giacomini M, Wo NC,
Szeto HH, Ben Mimoun M, Andres M, Gaillard RC, Guillon G,
Manning M. 2002. [1-deamino-4-cyclohexylalanine] arginine
vasopressin: Ap otent and speciﬁc agonist for vasopressin V1b
receptors. Endocrinology 143:4655–4664.
Dinan TG, Scott LV.2 005. Anatomyo fm elancholia:F ocus on
hypothalamic–pituitary–adrenal axis overactivity and the role of
vasopressin. JA nat 207:259–264.
Domokos A, Mergl Z, Barna I, Makara GB, Zelena D. 2008.
Congenital vasopressin deﬁciency and acute and chronic opiate
effectso nh ypothalamo–pituitary–adrenal axis activity in
Brattleboro rats.JE ndocrinol 196:113–121.
Egashira N, Tanoue A, Higashihara F, Fuchigami H, Sano K,
Mishima K, Fukue Y, Nagai H, Takano Y, Tsujimoto G,
Stemmelin J, Griebel G, Iwasaki K, Ikeda T, Nishimura R,
Fujiwara M. 2005. Disruption of the prepulse inhibitiono ft he
startle reﬂex in vasopressin V1b receptor knockout mice:
Reversal by antipsychotic drugs.N europsychopharmacology
30:1996–2005.
Ehrhart-Bornstein M, Hinson JP,B ornstein SR, ScherbaumW A,
Vinson GP.1 998. Intraadrenal interactions in the regulation
of adrenocortical steroidogenesis. Endocr Rev 19:101–143.
Engin E, Treit D. 2008. Dissociation of the anxiolytic-like effects of
Avpr1a and Avpr1b receptor antagonists in the dorsal and
ventral hippocampus.N europeptides4 2:411–421.
Engler D, Pham T, Fullerton MJ, Ooi G, Funder JW,C larke IJ.
1989. Studies of the secretion of corticotropin-releasing factor
and arginine vasopressin into the hypophysial-portal circulation
of the conscious sheep.I .E ffect of an audiovisual stimulus and
insulin-induced hypoglycemia. Neuroendocrinology4 9:
367–381.
Ferris CF,M elloni RH, Koppel G, PerryK W, Fuller RW,D elville Y.
1997. Vasopressin/serotonin interactions in the anterior hypo-
thalamusc ontrol aggressiveb ehaviori ng oldenh amsters.
JN eurosci 17:4331–4340.
Ferris CF,L uS -F,M essenger T, Guillon CD,H eindel N, Miller M,
Koppel G, RobertB runs F, Simon NG. 2006. Orally active
vasopressinV 1a receptor antagonist,S RX251,s electively
blocks aggressiveb ehavior.P harmacol Biochem Behav 83:
169–174.
Folny V, Raufaste D, Lukovic L, Pouzet B, Rochard P, Pascal M,
Serradeil-Le Gal C. 2003. Pancreatic vasopressinV 1b
receptors: Characterization in In-R1-G9 cells and localization
in human pancreas.A mJPhysiol Endocrinol Metab 285:
E566–E576.
Fujiwara Y, Hiroyama M, Sanbe A, Aoyagi T, Birumachi J-I,
Yamauchi J, TsujimotoG ,T anoue A. 2007a. Insulin hypersen-
sitivity in mice lacking the V1b vasopressin receptor.JPhysiol
584:235–244.
Fujiwara Y, Hiroyama M, Sanbe A, Yamauchi J, Tsujimoto G,
Tanoue A. 2007b.M utual regulation of vasopressin-a nd
oxytocin-induced glucagon secretioni nV 1b vasopressin
receptor knockout mice. JE ndocrinol 192:361–369.
van Gaalen MM, Basso AM, BespalovA Y, Rueter LE, Oost T,
Breuer M, Olivier B, Beyerbach A, Gross G, Sullivan JP,
Schoemaker H, Wernet W. 2008. Antidepressant- and
anxiolytic-likee ffectso ft he vasopressinV 1b receptor
antagonists ABT-436 and ABT-558. In: Proceedings of Society
for Neuroscience, Washington DC, USA. Abstract#560.18/
FF6.
Gallo-Payet N, Guillon G. 1998. Regulation of adrenocortical
function by vasopressin. HormM etab Res 30:360–367.
Gillies GE, Linton EA, LowryP J. 1982. Corticotropin releasing
activity of then ew CRF is potentiated severalt imes by
vasopressin. Nature 299:355–357.
Grazzini E, Lodboerer AM, Perez-Martin A, JoubertD ,G uillon G.
1996.M oleculara nd functional characterizationo fV 1b
vasopressin receptor in rat adrenal medulla.E ndocrinology
137:3906–3914.
Grazzini E, Boccara G, JoubertD ,T rueba M, Durroux T,
GuillonG ,G allo-PayetN ,C houinardL ,P ayetM D,
SerradeilL eG al C. 1998.V asopressinr egulates adrenal
functions by acting through differentv asopressin receptor
subtypes.A dv Exp Med Biol 449:325–334.
GrazziniE,BretonC,DerickS,AndresM,RaufasteD, RickwaertF ,
Boccara G, Colson P, Gue ´ rineau NC, Serradeil-Le Gal C,
Guillon G. 1999. Vasopressin receptors in human adrenal
medulla and pheochromocytoma. JC lin Endocrinol Metab 84:
2195–2203.
Griebel G, Simiand J, Serradeil-Le Gal C, Wagnon J, Pascal M,
Scatton B, Maffrand J-P,S oubrie P. 2002. Anxiolytic-a nd
antidepressant-like effects of the non-peptide vasopressin V1b
receptor antagonist,S SR149415, suggesta ni nnovative
approach for the treatment of stress-related disorders. Proc
Natl Acad Sci USA 99:6370–6375.
Griebel G, Stemmelin J, Gal CS-L, Soubrie ´ P. 2005. Non-peptide
vasopressin V1b receptor antagonists as potential drugs for the
treatment of stress-related disorders. Curr PharmD es 11:
1549–1559.
Griffante C, Green A, Curcuruto O, Haslam CP,D ickinson BA,
Arban R. 2005. Selectivity of d[Cha4]AVP and SSR149415a t
human vasopressin ando xytocinr eceptors: Evidence that
SSR149415 is am ixed vasopressin V1b/oxytocin receptor
antagonist. Br JP harmacol 146:744–751.
GuillonG,TruebaM,JoubertD ,GrazziniE,ChouinardL,Co ˆ te ´ M,
PayetM D, ManzoniO ,B arberisC ,R obert M. 1995.
Vasopressin stimulates steroid secretion in human adrenal
glands: Comparison with angiotensin-II effect. Endocrinology
136:1285–1295.
Hammock EAD,Y oung LJ.2 002. Variation in the vasopressin V1a
receptor promoter and expression: Implicationsf or inter- and
intraspeciﬁc variation in social behaviour. Eur JN eurosci 16:
399–402.
Hammock EAD, YoungL J. 2005. Microsatellitei nstability
generates diversity in brain and sociobehavioral traits.S cience
308:1630–1634.
Harbuz MS, Lightman SL. 1992. Stress and the hypothalamo–
pituitary–adrenal axis:A cute,c hronica nd immunological
activation. JE ndocrinol 134:327–339.
Herman JP,F igueiredoH ,M ueller NK,U lrich-Lai Y,
Ostrander MM,C hoiD C, Cullinan WE.2 003. Central
mechanisms of stress integration: Hierarchicalc ircuitryc ontrol-
ling hypothalamo–pituitary–adrenocorticalr esponsiveness.
Front Neuroendocrinol 24:151–180.
Hernando F, Schoots O, Lolait SJ, Burbach JP.2 001. Immunohis-
tochemical localization of the vasopressin V1b receptor in the rat
brain and pituitaryg land: Anatomical supportf or its involve-
ment in the central effects of vasopressin. Endocrinology 142:
1659–1668.
Hodgson RA, Higgins GA, Guthrie DH, Lu SX, Pond AJ,
MullinsD E, Guzzi MF,P arker EM,V arty GB.2 007.
Comparison of the V1b antagonist, SSR149415, and the
CRF1 antagonist, CP-154,526,i nr odent models of anxiety
and depression. Pharmacol Biochem Behav 86:431–440.
Iijima M, Chaki S. 2007. An arginine vasopressin V1b antagonist,
SSR149415 elicits antidepressant-like effects in an olfactory
J. A. Roper et al. 112bulbectomym odel. Prog Neuropsychopharmacol Biol Psychia-
try3 1:622–627.
Ishizuka Y, Abe H, Tanoue A, Kannan H, Ishida Y. 2010.
Involvemento fv asopressinV 1b receptori na nti-anxiety
action of SSRI and SNRI in mice. Neurosci Res 66:233–237.
Itoh S, Yamada S, Mori T, Miwa T, Tottori K, Uwahodo Y,
YamamuraY, FukudaM,YamamotoK,TanoueA,TsujimotoG .
2006. Attenuated stress-induced catecholamine release in mice
lacking the vasopressin V1b receptor.A mJPhysiol Endocrinol
Metab 291:E147–E151.
Jard S, Gaillard RC, Guillon G, Marie J, Schoenenberg P,
Muller AF,M anning M, Sawyer WH. 1986. Vasopressin
antagonists allow demonstration of an ovel type of vasopressin
receptor in the rat adenohypophysis.M ol Pharmacol 30:
171–177.
Jard S, Barberis C, Audigier S, Tribollet E. 1987. Neurohypophy-
seal hormone receptor systems in brain and periphery. Prog
Brain Res 72:173–187.
JengY J, Lolait SJ, Strakova Z, Chen C, CoplandJ A, Mellman D,
Hellmich MR,S oloffM S. 1996.M olecularc loning and
functional characterization of the oxytocin receptor from ar at
pancreatic cell line (RINm5F).N europeptides 30:557–565.
Kalueff AV,W heaton M, Murphy DL. 2007. What’sw rong with my
mouse model? Advances and strategies in animal modeling of
anxiety and depression. Behav Brain Res 179:1–18.
Kirchhoff VD,N guyen HTT,S oczynskaJ K, Woldeyohannes HO,
McIntyre RS. 2009. Discontinued psychiatric drugs in 2008.
ExpertO pin Investig Drugs 18:1431–1443.
Kirk CJ, Rodrigues LM, Hems DA.1 979. The inﬂuence of
vasopressin and related peptides on glycogen phosphorylase
activity and phosphatidylinositol metabolism in hepatocytes.
Biochem J1 78:493–496.
Knepper MA. 1997. Molecularp hysiology of urinaryc oncentrating
mechanism:R egulationo fa quaporin water channels by
vasopressin. Am JP hysiol 272:F3–F12.
Koshimizu T-A, Nasa Y, Tanoue A, Oikawa R, Kawahara Y,
Kiyono Y, Adachi T, Tanaka T, Kuwaki T, MoriT ,T akeo S,
Okamura H, TsujimotoG .2 006. V1a vasopressin receptors
maintain normal blood pressure by regulating circulatingb lood
volume and baroreﬂex sensitivity.P roc Natl Acad Sci USA 103:
7807–7812.
Lemmens-Gruber R, Kamyar M. 2006. Vasopressin antagonists.
Cell Mol Life Sci 63:1766–1779.
Lolait SJ, O’Carroll A-M, Mahan LC, Felder CC, Button DC,
Young WS, Mezey E, Brownstein MJ.1 995. Extrapituitary
expression of the rat V1b vasopressin receptor gene. Proc Natl
Acad Sci USA 92:6783–6787.
Lolait SJ, StewartL Q, JessopD S, Young WS, O’Carroll A-M.
2007a. The hypothalamic–pituitary–adrenal axis response to
stress in mice lacking functional vasopressin V1b receptors.
Endocrinology 148:849–856.
LolaitSJ,StewartLQ,RoperJA,HarrisonG,JessopDS,YoungWS,
O’Carroll A-M. 2007b.A ttenuated stress response to acute
lipopolysaccharide challenge and ethanol administration in
vasopressin V1b receptor knockout mice. JN euroendocrinol
19:543–551.
Louis C, CohenC, Depoortere R, Griebel G. 2006. Antidepressant-
like effects of the corticotropin-releasing factor Ir eceptor
antagonist,S SR125543, andt he vasopressinI br eceptor
antagonist, SSR149415, in aD RL-72s schedule in the rat.
Neuropsychopharmacology 31:2180–2187.
Manning M, Stoev S, Chini B, Durroux T, Mouillac B, Guillon G.
2008. Peptide and non-peptidea gonists and antagonists for the
vasopressin and oxytocin V1a, V1b, V2 and OT receptors:
Research tools and potential therapeutic agents.P rog Brain Res
170:473–512.
Marti O, Armario A. 1998. Anterior pituitaryr esponse to stress:
Time-related changes and adaptation.I nt JD ev Neurosci 16:
241–260.
Ma X-M, Levy A, Lightman SL. 1997. Emergence of an isolated
arginine vasopressin (AVP) response to stress after repeated
restraint: As tudy of both AVPa nd corticotropin-releasing
hormone messenger ribonucleic acid (RNA) and heteronuclear
RNA. Endocrinology 138:4351–4357.
Ma X-M, Lightman SL, Aguilera G. 1999. Vasopressin and
corticotropin-releasing hormone gene responses to novel stress
in rats adapted to repeated restraint. Endocrinology 140:
3623–3632.
Mlynarik M,ZelenaD, BagdyG,MakaraGB, JezovaD .2 007.Signs
of attenuated depression-like behaviour in vasopressin deﬁcient
Brattleboro rats. HormB ehav 51:395–405.
MorelA ,O ’Carroll A-M, Brownstein MJ,L olaitS J. 1992.
Molecular cloninga nd expression of ar at V1aa rginine
vasopressin receptor.N ature 356:523–526.
Nakamura K, FujiwaraY ,M izutani R, Sanbe A, Miyauchi N,
Hiroyama M, Yamauchi J, Yamashita T, Nakamura S, Mori T,
Tsujimoto G, Tanoue A. 2008. Effects of vasopressin V1b
receptor deﬁciency on adrenocorticotropin release from anterior
pituitaryc ells in response to oxytocin stimulation. Endocrin-
ology 149:4883–4891.
O’Carroll A-M, Howell GM, Roberts EM, Lolait SJ.2 008.
Vasopressinp otentiates corticotropin-releasing hormone-
inducedi nsulinr elease from mousep ancreaticb eta-cells.
JE ndocrinol 197:231–239.
Oshikawa S, Tanoue A, Koshimizu T-A, Kitagawa Y, TsujimotoG .
2004. Vasopressin stimulates insulin release from islet cells
through V1b receptors: Ac ombined pharmacological/knockout
approach. Mol Pharmacol 65:623–629.
Ostrowski NL, Lolait SJ, Young WS. 1994. Cellular localization of
vasopressin V1a receptor messenger ribonucleic acid in adult
male rat brain, pineal,a nd brain vasculature. Endocrinology
135:1511–1528.
Overstreet DH, Griebel G. 2005. Antidepressant-like effects of
the vasopressin V1b receptor antagonist SSR149415 in the
Flinders SensitiveL ine rat. Pharmacol Biochem Behav 82:
223–227.
Pena A, Murat B, Trueba M, Ventura MA, Wo NC, Szeto HH,
Cheng LL, Stoev S, Guillon G, Manning M. 2007a. Design and
synthesis of the ﬁrsts electivea gonists for the rat vasopressin
V(1b) receptor: Based on modiﬁcations of deamino-[Cys1]ar-
ginine vasopressin at positions 4a nd 8. JM ed Chem 50:
835–847.
Pena A, Murat B, Trueba M, Ventura MA, Bertrand G, Cheng LL,
Stoev S, Szeto HH, Wo N, Brossard G, Serradeil-Le Gal C,
Manning M, Guillon G. 2007b.P harmacological and physio-
logical characterization of d[Leu4, Lys8]vasopressin, the ﬁrst
V1b-selectivea gonist for rat vasopressin/oxytocin receptors.
Endocrinology 148:4136–4146.
Plotsky PM, Bruhn TO,V ale W. 1985. Hypophysiotropic regulation
of adrenocorticotropin secretion in response to insulin-induced
hypoglycemia. Endocrinology 117:323–329.
RamosA T, Troncone LRP, Tuﬁk S. 2006. Suppression of
adrenocorticotrophic hormone secretion by simultaneous antag-
onism of vasopressin 1b and CRH-1 receptors on three different
stress models.N euroendocrinology 84:309–316.
Reversi A, CassoniP ,C hini B. 2005. Oxytocin receptor signaling in
myoepithelial andc ancer cells. JM ammary GlandB iol
Neoplasia 10:221–229.
Rivier C, Vale W. 1983. Interaction of corticotropin-releasing factor
anda rgininev asopressino na drenocorticotropin secretion
in vivo .E ndocrinology 113:939–942.
Saito M, Sugimoto T, Tahara A, Kawashima H. 1995. Molecular
cloning and characterization of rat V1b vasopressin receptor:
Evidence for its expression in extra-pituitary tissues.B iochem
Biophys Res Commun 212:751–757.
Salome ´ N, Stemmelin J, Cohen C, Griebel G. 2006. Differential
roles of amygdaloid nuclei in the anxiolytic- and antidepressant-
Function of vasopressin Avpr1b 113like effects of the V1b receptor antagonist, SSR149415, in rats.
Psychopharmacology 187:237–244.
Scattoni ML, McFarlane HG, Zhodzishsky V, Caldwell HK,
Young WS, Ricceri L, Crawley JN.2 008. Reduced ultrasonic
vocalizations in vasopressin 1b knockout mice. Behav Brain Res
187:371–378.
Schonberger M, Legget C, Kim SW,H ooker JM. 2010. Synthesis
of [
11C]SSR149415 and preliminaryi maging studies using
positron emission topography.B ioorg Med Chem Lett 20:
3103–3106.
Scott JD,M iller MW,L iS W, Lin S-I, Vaccaro HA, Hong L,
Mullins DE, Guzzi M, Wenstein J, Hodgson RA, VartyG B,
Stamford AW,C han T-Y, McKittrick BA, Greenlee WJ, Priestley
T, Parker EM. 2009. Tetrahydroquinolines ulfonamides as
vasopressin 1b receptor antagonists. Bioorg Med Chem Lett 19:
6018–6022.
Serradeil-Le Gal C, Wagnon J, Simiand J, Griebel G, Lacour C,
Guillon G, Barberis C, Brossard G, Soubrie ´ P, Nisato D,




mide (SSR149415), as electivea nd orally active vasopressin
V1br eceptora ntagonist.JP harmacol ExpT her3 00:
1122–1130.
Serradeil-Le Gal C, Raufaste D, Derick S, Blankenstein J, Allen J,
Pouzet B, Pascal M, Wagnon J, Ventura MA. 2007. Biological
characterizationo fr odenta nd humanv asopressinV 1b
receptorsu sing SSR-149415, an onpeptide V1b receptor
ligand. Am JP hysiol Regul Integr Comp Physiol 293:
R938–R949.
ShimazakiT ,I ijima M, Chaki S. 2006. The pituitarym ediates the
anxiolytic-like effectsofthevasopressinV1Breceptorantagonist,
SSR149415, in as ocial interaction test in rats. Eur JP harmacol
543:63–67.
SpigaF ,H arrisonL ,W oodS ,K nightD ,M acsweeneyC ,
Thomson F, Craighead M, Lightman SL. 2009a. Blockade of
the V1b receptor reduces ACTH, but not corticosterone,
secretion induced by stress without effecting basal HPAa xis
activity.JEndocrinol 200:273–283.
Spiga F, Harrison L, Macsweeney C, Thomson F, Craighead M,
Lightman S. 2009b.E ffect of vasopressin 1b receptor blockade
on the hypothalamic–pituitary–adrenal response of chronically
stressed rats to ah eterotypic stressor. JE ndocrinol2 00:
285–291.
Stemmelin J, Lukovic L, Salome ´ N, Griebel G. 2005. Evidence that
the lateral septum is involved in the antidepressant-like effects of
the vasopressin V1b receptor antagonist, SSR149415. Neurop-
sychopharmacology 30:35–42.
StewartL Q,RoperJA,YoungWS, O’Carroll A-M,LolaitSJ.2008a.
Pituitary–adrenal response to acute and repeated mild restraint,
forced swim and change in environment stress in arginine
vasopressin receptor 1b knockout mice. JN euroendocrinol 20:
597–605.
StewartL Q, Roper JA, Young WS, O’Carroll A-M, Lolait SJ.
2008b.T he role of the arginine vasopressin Avp1b receptor in
the acute neuroendocrinea ction of antidepressants.P sycho-
neuroendocrinology 33:405–415.
Subburaju S, Aguilera G. 2007. Vasopressin mediates mitogenic
responsest oa drenalectomy in ther at anterior pituitary.
Endocrinology 148:3102–3110.
Tanoue A, Ito S, Honda K, Oshikawa S, Kitagawa Y, Koshimizu T-
A, MoriT ,T sujimotoG .2 004. The vasopressin V1b receptor
critically regulates hypothalamic–pituitary–adrenal axis activity
under both stress and resting conditions.JClin Invest 113:
302–309.
ThibonnierM ,C oles P, Thibonnier A, Shoham M. 2001. The basic
and clinical pharmacology of nonpeptide vasopressin receptor
antagonists.A nnu Rev Pharmacol Toxicol 41:175–202.
Vaccari C, Lolait SJ, Ostrowski NL. 1998. Comparatived istribution
of vasopressin V1b and oxytocin receptor messenger ribonucleic
acids in brain. Endocrinology 139:5015–5033.
Ventura MA, Rene ´ P, de Keyzer Y, Bertagna X, Clauser E. 1999.
Gene and cDNA cloning and characterization of the mouse V3/
V1b pituitaryv asopressin receptor.JM ol Endocrinol 22:
251–260.
Volpi S, Rabadan-DiehlC ,C awley N, AguileraG .2 002.
Transcriptional regulation of the pituitaryv asopressin V1b
receptor involves aG AGA-binding protein. JB iol Chem 277:
27829–27838.
Volpi S, Rabada ´ n-Diehl C, Aguilera G. 2004a. Regulation of
vasopressin V1b receptors and stress adaptation. Ann NYAcad
Sci 1018:293–301.
Volpi S, Rabadan-Diehl C, Aguilera G. 2004b.V asopressinergic
regulation of the hypothalamic pituitarya drenal axis and stress
adaptation. Stress 7:75–83.
Wernet W, Hornberger WB, Unger LV,M eyer AH, Netz A, Oost T,
Hillen H, Hahn A, SchoemakerH ,B ackﬁsh G, Beyerbach A,
Sullivan JP.2 008. In vitro characterization of the selective
vasopressin V1b receptor antagonists ABT-436 and ABT-558.
In: Proceedings of Society for Neuroscience, WashingtonD C,
USA. Abstract#560.16/FF4.
Wersinger SR, Ginns EI, O’Carroll A-M, Lolait SJ, Young WS.
2002. Vasopressin V1b receptor knockout reduces aggressive
behaviori nm ale mice. Mol Psychiatry7 :975–984.
Wersinger SR, Kelliher KR, Zufall F, Lolait SJ, O’Carroll A-M,
Young WS. 2004. Social motivation is reduced in vasopressin 1b
receptor null mice despite normal performance in an olfactory
discrimination task. HormB ehav 46:638–645.
Wersinger SR, Caldwell HK, ChristiansenM ,Y oung WS. 2007a.
Disruption of the vasopressin 1b receptor gene impairs the attack
component of aggressiveb ehavior in mice. Genes Brain Behav 6:
653–660.
Wersinger SR, Caldwell HK, Martinez L, Gold P, Hsu SB,
Young WS. 2007b.V asopressin 1a receptor knockout mice have
as ubtle olfactoryd eﬁcit but normal aggression. Genes Brain
Behav 6:540–551.
Wersinger SR, Temple JL, Caldwell HK, Young WS. 2008.
Inactivation of the oxytocin and the vasopressin (Avp) 1b
receptor genes, but not the Avp1 ar eceptor gene, differentially
impairst he Bruce effect in laboratorym ice (Mus musculus).
Endocrinology 149:116–121.
van West D, Del-Favero J, Aulchenko Y, Oswald P, SoueryD ,
Forsgren T, Sluijs S, Bel-Kacem S, Adolfsson R, Mendlewicz J,
van Duijn C, Deboutte D, van Broeckhoven C, Claes S. 2004.
Am ajor SNP haplotypeo ft he arginine vasopressin 1B receptor
protects against recurrent major depression. Mol Psychiatry9 :
287–292.
vanWestD, Del-FaveroJ,DeboutteD, vanBroeckhovenC,ClaesS.
2009. Arginine vasopressin receptor-geneb ased single-nucleo-
tide polymorphism analysis in attention deﬁcit hyperactivity
disorder.P sychiatr Genet 19:102–103.
de Wied D, Diamant M, Fodor M. 1993. Central nervouss ystem
effects of the neurohypophyseal hormones and related peptides.
Front Neuroendocrinol 14:251–302.
WinslowJ T, HearnE F, Ferguson J, Young LJ, Matzuk MM,
Insel TR. 2000. Infant vocalization,a dult aggression, and fear
behaviour of an oxytocin null mutant mouse. HormB ehav3 7:
145–155.
Yang M, Scattoni ML, Zhodzishsky V, Chen T, Caldwell H,
Young WS, McFarlane HG, Crawley JN.2 007. Social Approach
Behaviorsa re Similar on Conventional Versus ReverseL ighting
Cycles, and in ReplicationsA cross Cohorts, in BTBR T þ tf/J,
C57BL/6J, and Vasopressin Receptor 1B Mutant Mice. Front
Behav Neurosci 1:1–9.
Yibchok-anun S, Hsu WH. 1998. Effects of arginine vasopressin
and oxytocin on glucagon release from clonal alpha-cell line
J. A. Roper et al. 114In-R1-G9:I nvolvemento fV 1b receptors. Life Sci6 3:
1871–1878.
Yibchok-anunS ,C heng H, HeineP A, HsuW H. 1999.
Characterization of receptors mediating AVP- and OT-induced
glucagon release from the rat pancreas.A mJPhysiol 277:
E56–E62.
Yibchok-anun S, Abu-Basha EA, YaoC -Y,P anichkriangkrai W,
Hsu WH. 2004. The role of arginine vasopressin in diabetes-
associated increase in glucagon secretion. Regul Pept 122:
157–162.
Young WS, Li J, Wersinger SR, Palkovits M. 2006. The vasopressin
1b receptor is prominent in the hippocampal area CA2 where it
is unaffected by restraint stress or adrenalectomy.N euroscience
143:1031–1039.
Young SF,G riffante C, Aguilera G. 2007. Dimerization between
vasopressin V1b and corticotropin releasing hormone type 1
receptors. Cell Mol Neurobiol 27:439–461.
Zelena D, Foldes A, Mergl Z, Barna I, Kovacs KJ, Makara GB.
2004. Effects of repeated restraint stress on hypothalamo–
pituitary–adrenocorticalf unction in vasopressind eﬁcient
Brattleboro rats. Brain Res Bull 63:521–530.
Zelena D, Domokos A, Barna I, Mergl Z, Haller J, Makara GB.
2008. Control of the hypothalamo–pituitary–adrenal axis in the
neonatal period: Adrenocorticotropin and corticosterone stress
responses dissociate in vasopressin-deﬁcient Brattleboro rats.
Endocrinology 149:2576–2583.
Zelena D, Domokos A, Jain S, Jankord R, Filaretova L. 2009. The
stimuli-speciﬁcr oleo fv asopressini nt he hypothalamo–
pituitary–adrenal axis response to stress.JE ndocrinol 202:
263–278.
Zhou Y, LeriF ,C ummins E, Hoeschele M, Kreek MJ.2 008.
Involvement of arginine vasopressin and V1b receptor in heroin
withdrawal and heroin seeking precipitated by stress and by
heroin. Neuropsychopharmacology 33:226–236.
Function of vasopressin Avpr1b 115